

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
1 September 2005 (01.09.2005)

PCT

(10) International Publication Number
WO 2005/079397 A2

(51) International Patent Classification: Not classified

(74) Agents: FEIT, Irving, N. et al.; Hoffmann & Baron, LLP,
6900 Jericho Turnpike, Syosset, NY 11791 (US).

(21) International Application Number:
PCT/US2005/004714

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 11 February 2005 (11.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/778,908 13 February 2004 (13.02.2004) US
10/845,057 13 May 2004 (13.05.2004) US

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **ROCKEFELLER UNIVERSITY** [US/US]; 1230 York Avenue, New York, NY 11021-6399 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **TUSCHL, Thomas, H.** [DE/US]; 504 East 63rd Street, #37R, New York, NY 10021 (US). **LANDTHALER, Markus** [DE/US]; 238 East 81st Street, #3A, New York, NY 10028 (US). **MEISTER, Gunter** [DE/US]; 500 East 63rd Street, New York, NY 10021 (US). **PFEFFER, Sebastien** [FR/US]; 10 River Road, #11C, New York, NY 10044 (US).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTI-MICRORNA OLIGONUCLEOTIDE MOLECULES

(57) Abstract: The invention relates to isolated anti-microRNA molecules. In another embodiment, the invention relates to an isolated microRNA molecule. In yet another embodiment, the invention provides a method for inhibiting microRNP activity in a cell.

WO 2005/079397 A2

Anti-MicroRNA Oligonucleotide Molecules

This application is a continuing application of U.S. Application Serial Number 10/778,908 filed on February 13, 2004. The specification of U.S. Application Serial Number 10/778,908 is hereby incorporated by reference in its entirety.

The invention claimed herein was made with the help of grant number 1 R01 GM068476-01 from NIH/NIGMS. The U.S. government has certain rights in the invention.

BACKGROUND OF THE INVENTION

RNA silencing is a fundamental mechanism of gene regulation that uses double-stranded RNA (dsRNA) derived 21- to 28-nucleotide (nt) small RNAs to guide mRNA degradation, control mRNA translation or chromatin modification. Recently, several hundred novel genes were identified in plants and animals that encode transcripts that contain short dsRNA hairpins.

Defined 22-nt RNAs, referred to as microRNAs (miRNAs), are reported to be excised by dsRNA specific endonucleases from the hairpin precursors. The miRNAs are incorporated into ribonucleoprotein particles (miRNPs).

Plant miRNAs target mRNAs containing sequence segments with high complementarity for degradation or suppress translation of partially complementary mRNAs. Animal miRNAs appear to act predominantly as translational repressors. However, animal miRNAs have also been reported to guide RNA degradation. This indicates that animal miRNPs act like small interfering RNA (siRNA)-induced silencing complexes (RISCs).

Understanding the biological function of miRNAs requires knowledge of their mRNA targets. Bioinformatic approaches have been used to predict mRNA targets, among which transcription factors and proapoptotic genes were prominent candidates. Processes such as *Notch* signaling, cell proliferation, morphogenesis and axon guidance appear to be controlled by miRNA genes.

Therefore, there is a need for materials and methods that can help elucidate the function of known and future microRNAs. Due to the ability of microRNAs to induce RNA degradation

or repress translation of mRNA which encode important proteins, there is also a need for novel compositions for inhibiting microRNA-induced cleavage or repression of mRNAs.

SUMMARY THE INVENTION

In one embodiment, the invention provides an isolated single stranded anti-microRNA molecule comprising a minimum of ten moieties and a maximum of fifty moieties on a molecular backbone, the molecular backbone comprising backbone units, each moiety comprising a base bonded to a backbone unit, each base forming a Watson-Crick base pair with a complementary base wherein at least ten contiguous bases have the same sequence as a sequence of bases in any one of the anti-microRNA molecules shown in Tables 1-4, except that up to thirty percent of the bases pairs may be wobble base pairs, and up to 10% of the contiguous bases may be additions, deletions, mismatches, or combinations thereof; no more than fifty percent of the contiguous moieties contain deoxyribonucleotide backbone units; the moiety in the molecule at the position corresponding to position 11 of the microRNA is non-complementary; and the molecule is capable of inhibiting microRNP activity.

In another embodiment, the invention provides a method for inhibiting microRNP activity in a cell, the microRNP comprising a microRNA molecule, the microRNA molecule comprising a sequences of bases complementary of the sequence of bases in a single stranded anti-microRNA molecule, the method comprising introducing into the cell the single-stranded anti-microRNA molecule comprising a sequence of a minimum of ten moieties and a maximum of fifty moieties on a molecular backbone, the molecular backbone comprising backbone units, each moiety comprising a base bonded to a backbone unit, each base forming a Watson-Crick base pair with a complementary base, wherein at least ten contiguous bases of the anti-microRNA molecule are complementary to the microRNA, except that up to thirty percent of the bases may be substituted by wobble base pairs, and up to ten percent of the at least ten moieties may be additions, deletions, mismatches, or combinations thereof; no more than fifty percent of the contiguous moieties contain deoxyribonucleotide backbone units; and the moiety in the molecule at the position corresponding to position 11 of the microRNA is non-complementary.

In another embodiment, the invention provides an isolated microRNA molecule comprising a minimum of ten moieties and a maximum of fifty moieties on a molecular

backbone, the molecular backbone comprising backbone units, each moiety comprising a base bonded to a backbone unit, wherein at least ten contiguous bases have the same sequence as a sequence of bases in any one of the microRNA molecules shown in Table 2, except that up to thirty percent of the bases pairs may be wobble base pairs, and up to 10% of the contiguous bases may be additions, deletions, mismatches, or combinations thereof; and no more than fifty percent of the contiguous moieties contain deoxyribonucleotide backbone units.

In another embodiment, the invention provides an isolated microRNA molecule comprising a minimum of ten moieties and a maximum of fifty moieties on a molecular backbone, the molecular backbone comprising backbone units, each moiety comprising a base bonded to a backbone unit, wherein at least ten contiguous bases have any one of the microRNA sequences shown in Tables 1, 3 and 4, except that up to thirty percent of the bases pairs may be wobble base pairs, and up to 10% of the contiguous bases may be additions, deletions, mismatches, or combinations thereof; no more than fifty percent of the contiguous moieties contain deoxyribonucleotide backbone units; and is modified for increased nuclease resistance.

In yet another embodiment, the invention provides an isolated single stranded anti-microRNA molecule comprising a minimum of ten moieties and a maximum of fifty moieties on a molecular backbone, the molecular backbone comprising backbone units, each moiety comprising a base bonded to a backbone unit, each base forming a Watson-Crick base pair with a complementary base wherein at least ten contiguous bases have the same sequence as a sequence of bases in any one of the anti-microRNA molecules shown in Tables 1-4, except that up to thirty percent of the bases pairs may be wobble base pairs, and up to 10% of the contiguous bases may be additions, deletions, mismatches, or combinations thereof; no more than fifty percent of the contiguous moieties contain deoxyribonucleotide backbone units; and the molecule is capable of inhibiting microRNP activity.

In yet a further embodiment, the invention provides a method for inhibiting microRNP activity in a cell, the microRNP comprising a microRNA molecule, the microRNA molecule comprising a sequences of bases complementary of the sequence of bases in a single stranded anti-microRNA molecule, the method comprising introducing into the cell the single-stranded anti-microRNA molecule comprising a sequence of a minimum of ten moieties and a maximum

of fifty moieties on a molecular backbone, the molecular backbone comprising backbone units, each moiety comprising a base bonded to a backbone unit, each base forming a Watson-Crick base pair with a complementary base, wherein at least ten contiguous bases of the anti-microRNA molecule are complementary to the microRNA, except that up to thirty percent of the bases may be substituted by wobble base pairs, and up to ten percent of the at least ten moieties may be additions, deletions, mismatches, or combinations thereof; and no more than fifty percent of the contiguous moieties contain deoxyribonucleotide backbone units.

DESCRIPTION OF THE FIGURES

Figure 1 shows the modified nucleotide units discussed in the specification. B denotes any one of the following nucleic acid bases: adenosine, cytidine, guanosine, thymine, or uridine.

Figure 2. Antisense 2'-O-methyl oligoribonucleotide specifically inhibit miR-21 guided cleavage activity in HeLa cell S100 cytoplasmic extracts. The black bar to the left of the RNase T1 ladder represents the region of the target RNA complementary to miR-21. Oligonucleotides complementary to miR-21 were pre-incubated in S100 extracts prior to the addition of ³²P-labelled cleavage substrate. Cleavage bands and T1 hydrolysis bands appear as doublets after a 1-nt slipping of the T7 RNA polymerase near the middle of the transcript indicated by the asterisk.

Figure 3. Antisense 2'-O-methyl oligoribonucleotides interfere with endogenous miR-21 RNP cleavage in HeLa cells. HeLa cells were transfected with pHcRed and pEGFP or its derivatives, with or without inhibitory or control oligonucleotides. EGFP and HcRed protein fluorescence were excited and recorded individually by fluorescence microscopy 24 h after transfection. Co-expression of co-transfected reporter plasmids was documented by superimposing of the fluorescence images in the right panel.

DETAILED DESCRIPTION OF THE INVENTION

The invention relates to an isolated single stranded anti-microRNA molecule. The molecule comprises a minimum number of ten moieties, preferably a minimum of thirteen, more preferably a minimum of fifteen, even more preferably a minimum of 18, and most preferably a minimum of 21 moieties.

The anti-microRNA molecule comprises a maximum number of fifty moieties, preferably a maximum of forty, more preferably a maximum of thirty, even more preferably a maximum of twenty-five, and most preferably a maximum of twenty-three moieties. A suitable range of minimum and maximum number of moieties may be obtained by combining any of the above minima with any of the above maxima.

Each moiety comprises a base bonded to a backbone unit. In this specification, a base refers to any one of the nucleic acid bases present in DNA or RNA. The base can be a purine or pyrimidine. Examples of purine bases include adenine (A) and guanine (G). Examples of pyrimidine bases include thymine (T), cytosine (C) and uracil (U). Each base of the moiety forms a Watson-Crick base pair with a complementary base.

Watson-Crick base pairs as used herein refers to the hydrogen bonding interaction between, for example, the following bases: adenine and thymine (A = T); adenine and uracil (A = U); and cytosine and guanine (C = G). The adenine can be replaced with 2,6-diaminopurine without compromising base-pairing.

The backbone unit may be any molecular unit that is able stably to bind to a base and to form an oligomeric chain. Suitable backbone units are well known to those in the art.

For example, suitable backbone units include sugar-phosphate groups, such as the sugar-phosphate groups present in ribonucleotides, deoxyribonucleotides, phosphorothioate deoxyribose groups, N'3-N'5 phosphoroamidate deoxyribose groups, 2'-O-alkyl-ribose phosphate groups, 2'-O-alkyl-alkoxy ribose phosphate groups, ribose phosphate group containing a methylene bridge, 2'-Fluororibose phosphate groups, morpholino phosphoroamidate groups, cyclohexene groups, tricyclo phosphate groups, and amino acid molecules.

In one embodiment, the anti-microRNA molecule comprises at least one moiety which is a ribonucleotide moiety or a deoxyribonucleotide moiety.

In another embodiment, the anti-microRNA molecule comprises at least one moiety which confers increased nuclease resistance. The nuclease can be an exonuclease, an endonuclease, or both. The exonuclease can be a 3'→5' exonuclease or a 5'→3' exonuclease. Examples of 3'→5' human exonuclease include PNPT1, Werner syndrome helicase, RRP40,

RRP41, RRP42, RRP45, and RRP46. Examples of 5'→3' exonuclease include XRN2, and FEN1. Examples of endonucleases include Dicer, Drosha, RNase4, Ribonuclease P, Ribonuclease H1, DHP1, ERCC-1 and OGG1. Examples of nucleases which function as both an exonuclease and an endonuclease include APE1 and EXO1.

An anti-microRNA molecule comprising at least one moiety which confers increased nuclease resistance means a sequence of moieties wherein at least one moiety is not recognized by a nuclease. Therefore, the nuclease resistance of the molecule is increased compared to a sequence containing only unmodified ribonucleotide, unmodified deoxyribonucleotide or both. Such modified moieties are well known in the art, and were reviewed, for example, by Kurreck, *Eur. J. Biochem.* 270, 1628-1644 (2003).

A modified moiety can occur at any position in the anti-microRNA molecule. For example, to protect the anti-microRNA molecule against 3'→5' exonucleases, the molecule can have at least one modified moiety at the 3' end of the molecule and preferably at least two modified moieties at the 3' end. If it is desirable to protect the molecule against 5'→3' exonuclease, the anti-microRNA molecule can have at least one modified moiety and preferably at least two modified moieties at the 5' end of the molecule. The anti-microRNA molecule can also have at least one and preferably at least two modified moieties between the 5' and 3' end of the molecule to increase resistance of the molecule to endonucleases. In one embodiment, all of the moieties are nuclease resistant.

In another embodiment, the anti-microRNA molecule comprises at least one modified deoxyribonucleotide moiety. Suitable modified deoxyribonucleotide moieties are known in the art.

A suitable example of a modified deoxyribonucleotide moiety is a phosphorothioate deoxyribonucleotide moiety. See structure 1 in figure 1. An anti-microRNA molecule comprising more than one phosphorothioate deoxyribonucleotide moiety is referred to as phosphorothioate (PS) DNA. See, for example, Eckstein, *Antisense Nucleic Acids Drug Dev.* 10, 117-121 (2000).

Another suitable example of a modified deoxyribonucleotide moiety is an N³-N⁵ phosphoroamidate deoxyribonucleotide moiety. See structure 2 in figure 1. An oligonucleotide molecule comprising more than one phosphoroamidate deoxyribonucleotide moiety is referred to as phosphoroamidate (NP) DNA. See, for example, Gryaznov *et al.*, J. Am. Chem. Soc. *116*, 3143-3144 (1994).

In another embodiment, the molecule comprises at least one modified ribonucleotide moiety. Suitable modified ribonucleotide moieties are known in the art.

A suitable example of a modified ribonucleotide moiety is a ribonucleotide moiety that is substituted at the 2' position. The substituents at the 2' position may, for example, be a C₁ to C₄ alkyl group. The C₁ to C₄ alkyl group may be saturated or unsaturated, and unbranched or branched. Some examples of C₁ to C₄ alkyl groups include ethyl, isopropyl, and allyl. The preferred C₁ to C₄ alkyl group is methyl. See structure 3 in figure 1. An oligoribonucleotide molecule comprising more than one ribonucleotide moiety that is substituted at the 2' position with a C₁ to C₄ alkyl group is referred to as a 2'-O-(C₁-C₄ alkyl) RNA, e.g., 2'-O-methyl RNA (OMe RNA).

Another suitable example of a substituent at the 2' position of a modified ribonucleotide moiety is a C₁ to C₄ alkoxy - C₁ to C₄ alkyl group. The C₁ to C₄ alkoxy (alkyloxy) and C₁ to C₄ alkyl group may comprise any of the alkyl groups described above. The preferred C₁ to C₄ alkoxy - C₁ to C₄ alkyl group is methoxyethyl. See structure 4 in figure 1. An oligonucleotide molecule comprising more than one ribonucleotide moiety that is substituted at the 2' position with a C₁ to C₄ alkoxy-C₁ to C₄ alkyl group is referred to as a 2'-O-(C₁ to C₄ alkoxy - C₁ to C₄ alkyl) RNA, e.g., 2'-O-methoxyethyl RNA (MOE RNA).

Another suitable example of a modified ribonucleotide moiety is a ribonucleotide that has a methylene bridge between the 2'-oxygen atom and the 4'-carbon atom. See structure 5 in figure 1. An oligoribonucleotide molecule comprising more than one ribonucleotide moiety that has a methylene bridge between the 2'-oxygen atom and the 4'-carbon atom is referred to as locked nucleic acid (LNA). See, for example, Kurreck *et al.*, Nucleic Acids Res. *30*, 1911-1918 (2002); Elayadi *et al.*, Curr. Opinion Invest. Drugs *2*, 558-561 (2001); Ørum *et al.*, Curr. Opinion Mol. Ther. *3*, 239-243 (2001); Koshkin *et al.*, Tetrahedron *54*, 3607-3630 (1998); Obika *et al.*,

Tetrahedron Lett.39, 5401-5404 (1998). Locked nucleic acids are commercially available from Proligo (Paris, France and Boulder, Colorado, USA).

Another suitable example of a modified ribonucleotide moiety is a ribonucleotide that is substituted at the 2' position with fluoro group. A modified ribonucleotide moiety having a fluoro group at the 2' position is a 2'-fluororibonucleotide moiety. Such moieties are known in the art. Molecules comprising more than one 2'-fluororibonucleotide moiety are referred to herein as 2'-fluororibo nucleic acids (FANA). See structure 7 in figure 1. Damha *et al.*, J. Am. Chem. Soc. 120, 12976-12977 (1998).

In another embodiment, the anti-microRNA molecule comprises at least one base bonded to an amino acid residue. Moieties that have at least one base bonded to an amino acid residue will be referred to herein as peptide nucleic acid (PNA) moieties. Such moieties are nuclease resistance, and are known in the art. Molecules having more than one PNA moiety are referred to as peptide nucleic acids. See structure 6 in figure 1. Nielson, Methods Enzymol. 313, 156-164 (1999); Elayadi, *et al*, *id.*; Braasch *et al.*, Biochemistry 41, 4503-4509 (2002), Nielsen *et al.*, Science 254, 1497-1500 (1991).

The amino acids can be any amino acid, including natural or non-natural amino acids. Naturally occurring amino acids include, for example, the twenty most common amino acids normally found in proteins, i.e., alanine (Ala), arginine (Arg), asparagine (Asn), aspartic acid (Asp), cysteine (Cys), glutamine (Glu), glutamic acid (Glu), glycine (Gly), histidine (His), isoleucine (Ileu), leucine (Leu), lysine (Lys), methionine (Met), phenylalanine (Phe), proline (Pro), serine (Ser), threonine (Thr), tryptophan, (Trp), tyrosine (Tyr), and valine (Val).

The non-natural amino acids may, for example, comprise alkyl, aryl, or alkylaryl groups. Some examples of alkyl amino acids include α -aminobutyric acid, β -aminobutyric acid, γ -aminobutyric acid, δ -aminovaleric acid, and ϵ -aminocaproic acid. Some examples of aryl amino acids include ortho-, meta, and para-aminobenzoic acid. Some examples of alkylaryl amino acids include ortho-, meta-, and para-aminophenylacetic acid, and γ -phenyl- β -aminobutyric acid.

Non-naturally occurring amino acids also include derivatives of naturally occurring amino acids. The derivative of a naturally occurring amino acid may, for example, include the addition or one or more chemical groups to the naturally occurring amino acid.

For example, one or more chemical groups can be added to one or more of the 2', 3', 4', 5', or 6' position of the aromatic ring of a phenylalanine or tyrosine residue, or the 4', 5', 6', or 7' position of the benzo ring of a tryptophan residue. The group can be any chemical group that can be added to an aromatic ring. Some examples of such groups include hydroxyl, C₁-C₄ alkoxy, amino, methylamino, dimethylamino, nitro, halo (i.e., fluoro, chloro, bromo, or iodo), or branched or unbranched C₁-C₄ alkyl, such as methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, or t-butyl.

Furthermore, other examples of non-naturally occurring amino acids which are derivatives of naturally occurring amino acids include norvaline (Nva), norleucine (Nle), and hydroxyproline (Hyp).

The amino acids can be identical or different from one another. Bases are attached to the amino acid unit by molecular linkages. Examples of linkages are methylene carbonyl, ethylene carbonyl and ethyl linkages. (Nielsen et al., *Peptide Nucleic Acids-Protocols and Applications*, Horizon Scientific Press, pages 1-19; Nielsen et al., *Science* 254: 1497-1500.)

One example of a PNA moiety is N-(2-aminoethyl)-glycine. Further examples of PNA moieties include cyclohexyl PNA, retro-inverso, phosphone, propionyl and aminoproline PNA.

PNA can be chemically synthesized by methods known in the art, e.g. by modified Fmoc or tBoc peptide synthesis protocols. The PNA has many desirable properties, including high melting temperatures (T_m), high base-pairing specificity with nucleic acid and an uncharged molecular backbone. Additionally, the PNA does not confer RNase H sensitivity on the target RNA, and generally has good metabolic stability.

Peptide nucleic acids are also commercially available from Applied Biosystems (Foster City, California, USA):

In another embodiment, the anti-microRNA molecule comprises at least one morpholino phosphoroamidate nucleotide moiety. A morpholino phosphoroamidate nucleotide moiety is a modified moiety which is nuclease resistant. Such moieties are known in the art. Molecules comprising more than one morpholino phosphoroamidate nucleotide moiety are referred to as morpholino (MF) nucleic acids. See structure 8 in figure 1. Heasman, *Dev. Biol.* 243, 209-214 (2002). Morpholino oligonucleotides are commercially available from Gene Tools LLC (Corvallis, Oregon, USA).

In another embodiment, the anti-microRNA molecule comprises at least one cyclohexene nucleotide moiety. A cyclohexene nucleotide moiety is a modified moiety which is nuclease resistant. Such moieties are known in the art. Molecules comprising more than one cyclohexene nucleotide moiety are referred to as cyclohexene nucleic acids (CeNA). See structure 10 in figure 1. Wang *et al.*, *J. Am. Chem. Soc.* 122, 8595-8602 (2000), Verbeure *et al.*, *Nucleic Acids Res.* 29, 4941-4947 (2001).

In another embodiment, the anti-microRNA molecule comprises at least one tricyclo nucleotide moiety. A tricyclo nucleotide moiety is a modified moiety which is nuclease resistant. Such moieties are known in the art. Steffens *et al.*, *J. Am. Chem. Soc.* 119, 11548-11549 (1997), Renneberg *et al.*, *J. Am. Chem. Soc.* 124, 5993-6002 (2002). Molecules comprising more than one tricyclo nucleotide moiety are referred to as tricyclo nucleic acids (tcDNA). See structure 9 in figure 1.

In another embodiment, to increase nuclease resistance of the anti-microRNA molecules of the present invention to exonucleases, inverted nucleotide caps can be attached to the 5' end, the 3' end, or both ends of the molecule. An inverted nucleotide cap refers to a 3'→5' sequence of nucleic acids attached to the anti-microRNA molecule at the 5' and/or the 3' end. There is no limit to the maximum number of nucleotides in the inverted cap just as long as it does not interfere with binding of the anti-microRNA molecule to its target microRNA. Any nucleotide can be used in the inverted nucleotide cap. Typically, the inverted nucleotide cap is one nucleotide in length. The nucleotide for the inverted cap is generally thymine, but can be any nucleotide such as adenine, guanine, uracil, or cytosine.

Alternatively, an ethylene glycol compound and/or amino linkers can be attached to the either or both ends of the anti-microRNA molecule. Amino linkers can also be used to increase nuclease resistance of the anti-microRNA molecules to endonucleases. The table below lists some examples of amino linkers. The below listed amino linker are commercially available from TriLink Biotechnologies, San Diego, CA.

2'-Deoxycytidine-5-C6 Amino Linker (3' Terminus)
2'-Deoxycytidine-5-C6 Amino Linker (5' or Internal)
3' C3 Amino Linker
3' C6 Amino Linker
3' C7 Amino Linker
5' C12 Amino Linker
5' C3 Amino Linker
5' C6 Amino Linker
C7 Internal Amino Linker
Thymidine-5-C2 Amino Linker (5' or Internal)
Thymidine-5-C6 Amino Linker (3' Terminus)
Thymidine-5-C6 Amino Linker (Internal)

Chimeric anti-microRNA molecules containing a mixture of any of the moieties mentioned above are also known, and may be made by methods known, in the art. See, for example, references cited above, and Wang *et al.*, Proc. Natl. Acad. Sci. USA 96, 13989-13994 (1999), Liang *et al.*, Eur. J. Biochem. 269, 5753-5758 (2002), Lok *et al.*, Biochemistry 41, 3457-3467 (2002), and Damha *et al.*, J. Am. Chem. Soc. 120, 12976-12977 (2002).

The molecules of the invention comprise at least ten contiguous, preferably at least thirteen contiguous, more preferably at least fifteen contiguous, and even more preferably at least twenty contiguous bases that have the same sequence as a sequence of bases in any one of the anti-microRNA molecules shown in Tables 1-4. The anti-microRNA molecules optimally

comprise the entire sequence of any one of the anti-microRNA molecule sequences shown in Tables 1-4.

For the contiguous bases mentioned above, up to thirty percent of the base pairs may be substituted by wobble base pairs. As used herein, wobble base pairs refers to either: i) substitution of a cytosine with a uracil, or 2) the substitution of a adenine with a guanine, in the sequence of the anti-microRNA molecule. These wobble base pairs are generally referred to as UG or GU wobbles. Below is a table showing the number of contiguous bases and the maximum number of wobble base pairs in the anti-microRNA molecule:

Table for Number of Wobble Bases

No. of Contiguous Bases	10	11	12	13	14	15	16	17	18
Max. No. of Wobble Base Pairs	3	3	3	3	4	4	4	5	5

No. of Contiguous Bases	19	20	21	22	23
Max. No. of Wobble Base Pairs	5	6	6	6	6

Further, up to ten percent, and preferably up to five percent of the contiguous bases can be additions, deletions, mismatches or combinations thereof. Additions refer to the insertion in the contiguous sequence of any moiety described above comprising any one of the bases described above. Deletions refer to the removal of any moiety present in the contiguous sequence. Mismatches refer to the substitution of one of the moieties comprising a base in the contiguous sequence with any of the above described moieties comprising a different base.

The additions, deletions or mismatches can occur anywhere in the contiguous sequence, for example, at either end of the contiguous sequence or within the contiguous sequence of the anti-microRNA molecule. If the contiguous sequence is relatively short, such as from about ten

to about 15 moieties in length, preferably the additions, deletions or mismatches occur at the end of the contiguous sequence. If the contiguous sequence is relatively long, such as a minimum of sixteen contiguous sequences, then the additions, deletions, or mismatches can occur anywhere in the contiguous sequence. Below is a table showing the number of contiguous bases and the maximum number of additions, deletions, mismatches or combinations thereof:

Table for Up to 10%

No. of Contiguous Bases	10	11	12	13	14	15	16	17	18
Max. No. of Additions, Deletions and/or Mismatches	1	1	1	1	1	1	1	1	1

No. of Contiguous Bases	19	20	21	22	23
Max. No. of Additions, Deletions and/or Mismatches	1	2	2	2	2

Table for Up to 5%

No. of Contiguous Bases	10	11	12	13	14	15	16	17	18
Max. No. of Additions, Deletions and/or Mismatches	0	0	0	0	0	0	0	0	0

No. of Contiguous Bases	19	20	21	22	23
Max. No. of Additions, Deletions and/or Mismatches	0	1	1	1	1

Furthermore, no more than fifty percent, and preferably no more than thirty percent, of the contiguous moieties contain deoxyribonucleotide backbone units. Below is a table showing the number of contiguous bases and the maximum number of deoxyribonucleotide backbone units:

Table for Fifty Percent Deoxyribonucleotide Backbone Units

No. of Contiguous Bases	10	11	12	13	14	15	16	17	18
Max. No. of Deoxyribonucleotide Backbone Units	5	5	6	6	7	7	8	8	9

No. of Contiguous Bases	19	20	21	22	23
Max. No. of Deoxyribonucleotide Backbone Units	9	10	10	11	11

Table for Thirty Percent Deoxyribonucleotide Backbone Units

No. of Contiguous Bases	10	11	12	13	14	15	16	17	18
Max. No. of Deoxyribonucleotide Backbone Units	3	3	3	3	4	4	4	5	5

No. of Contiguous Bases	19	20	21	22	23
Max. No. of Deoxyribonucleotide Backbone Units	5	6	6	6	6

The moiety in the anti-RNA molecule at the position corresponding to position 11 of the microRNA is optionally non-complementary to a microRNA. The moiety in the anti-microRNA molecule corresponding to position 11 of the microRNA can be rendered non-complementary by an addition, deletion or mismatch as described above.

In another embodiment, if the anti-microRNA molecule comprises only unmodified moieties, then the anti-microRNA molecules comprises at least one base, in the at least ten contiguous bases, which is non-complementary to the microRNA and/or comprises an inverted nucleotide cap, ethylene glycol compound or an amino linker.

In yet another embodiment, if the at least ten contiguous bases in an anti-microRNA molecule is perfectly (i.e., 100%) complementary to ten contiguous bases in a microRNA, then the anti-microRNA molecule contains at least one modified moiety in the at least ten contiguous bases and/or comprises an inverted nucleotide cap, ethylene glycol compound or an amino linker.

As stated above, the maximum length of the anti-microRNA molecule is 50 moieties. Any number of moieties having any base sequence can be added to the contiguous base sequence. The additional moieties can be added to the 5' end, the 3' end, or to both ends of the contiguous sequence.

MicroRNA molecules are derived from genomic loci and are produced from specific microRNA genes. Mature microRNA molecules are processed from precursor transcripts that form local hairpin structures. The hairpin structures are typically cleaved by an enzyme known as Dicer, which generates one microRNA duplex. See Bartel, Cell 116, 281-297 (2004) for a review on microRNA molecules. The article by Bartel is hereby incorporated by reference.

Each strand of a microRNA is packaged in a microRNA ribonucleoprotein complex (microRNP). A microRNP in, for example, humans, also includes the proteins eIF2C2, the helicase Gemin3, and Gemin 4.

The sequence of bases in the anti-microRNA molecules of the present invention can be derived from a microRNA from any species e.g. such as a fly (e.g., *Drosophila melanogaster*), a worm (e.g., *C. elegans*). Preferably the sequence of bases is found in mammals, especially humans (*H. sapiens*), mice (e.g., *M. musculus*), and rats (*R. norvegicus*).

The anti-microRNA molecule is preferably isolated, which means that it is essentially free of other nucleic acids. Essentially free from other nucleic acids means that it is at least 90%, preferably at least 95% and, more preferably, at least 98% free of other nucleic acids.

Preferably, the molecule is essentially pure, which means that the molecules is free not only of other nucleic acids, but also of other materials used in the synthesis of the molecule, such as, for example, enzymes used in the synthesis of the molecule. The molecule is at least 90% free, preferably at least 95% free and, more preferably, at least 98% free of such materials.

The anti-microRNA molecules of the present invention are capable of inhibiting microRNP activity, preferable in a cell. Inhibiting microRNP activity refers to the inhibition of cleavage of the microRNA's target sequence or the repression of translation of the microRNA's target sequence. The method comprises introducing into the cell a single-stranded microRNA molecule.

Any anti-microRNA molecule can be used in the methods of the present invention, as long as the anti-microRNA is complementary, subject to the restrictions described above, to the microRNA present in the microRNP. Such anti-microRNAs include, for example, the anti-

microRNA molecules mentioned above (see Table 1-4), and the anti-microRNAs molecules described in international PCT application number WO 03/029459 A2, the sequences of which are incorporated herein by reference.

The invention also includes any one of the microRNA molecules having the sequences as shown in Table 2. The novel microRNA molecules in Table 2 may optionally be modified as described above for anti-microRNA molecules. The other microRNA molecules in Tables 1, 3 and 4 are modified for increased nuclease resistance as described above for anti-microRNA molecules.

Utility

The anti-microRNA molecules and the microRNA molecules of the present invention have numerous *in vivo*, *in vitro*, and *ex vivo* applications.

For example, the anti-microRNA molecules and microRNA of the present invention may be used as a modulator of the expression of genes which are at least partially complementary to the anti-microRNA molecules and microRNA. For example, if a particular microRNA is beneficial for the survival of a cell, an appropriate isolated microRNA of the present invention may be introduced into the cell to promote survival. Alternatively, if a particular microRNA is harmful (e.g., induces apoptosis, induces cancer, etc.), an appropriate anti-microRNA molecule can be introduced into the cell in order to inhibit the activity of the microRNA and reduce the harm.

In addition, anti-microRNA molecules and/or microRNAs of the present invention can be introduced into a cell to study the function of the microRNA. Any of the anti-microRNA molecules and/or microRNAs listed above can be introduced into a cell for studying their function. For example, a microRNA in a cell can be inhibited with a suitable anti-microRNA molecule. The function of the microRNA can be inferred by observing changes associated with inhibition of the microRNA in the cell in order to inhibit the activity of the microRNA and reduce the harm.

The cell can be any cell which expresses microRNA molecules, including the microRNA molecules listed herein. Alternatively, the cell can be any cell transfected with an expression vector containing the nucleotide sequence of a microRNA.

Examples of cells include, but are not limited to, endothelial cells, epithelial cells, leukocytes (e.g., T cells, B cells, neutrophils, macrophages, eosinophils, basophils, dendritic cells, natural killer cells and monocytes), stem cells, hemopoietic cells, embryonic cells, cancer cells.

The anti-microRNA molecules or microRNAs can be introduced into a cell by any method known to those skilled in the art. Useful delivery systems, include for example, liposomes and charged lipids. Liposomes typically encapsulate oligonucleotide molecules within their aqueous center. Charged lipids generally form lipid- oligonucleotide molecule complexes as a result of opposing charges.

These liposomes-oligonucleotide molecule complexes or lipid- oligonucleotide molecule complexes are usually internalized by endocytosis. The liposomes or charged lipids generally comprise helper lipids which disrupt the endosomal membrane and release the oligonucleotide molecules.

Other methods for introducing an anti-microRNA molecule or a microRNA into a cell include use of delivery vehicles, such as dendrimers, biodegradable polymers, polymers of amino acids, polymers of sugars, and oligonucleotide-binding nanoparticles. In addition, pluronic gel as a depot reservoir can be used to deliver the anti-microRNA oligonucleotide molecules over a prolonged period. The above methods are described in, for example, Hughes et al., *Drug Discovery Today* 6, 303-315 (2001); Liang et al. *Eur. J. Biochem.* 269 5753-5758 (2002); and Becker et al., In *Antisense Technology in the Central Nervous System* (Leslie, R.A., Hunter, A.J. & Robertson, H.A., eds), pp.147-157, Oxford University Press.

Targeting of an anti-microRNA molecule or a microRNA to a particular cell can be performed by any method known to those skilled in the art. For example, the anti-microRNA molecule or microRNA can be conjugated to an antibody or ligand specifically recognized by receptors on the cell.

The sequences of microRNA and anti-microRNA molecules are shown in Tables 1-4 below. Human sequences are indicated with the prefix "hsa." Mouse sequences are indicated with the prefix "mmu." Rat sequences are indicated with the prefix "rno." *C. elegans* sequences are indicated with the prefix "cel." Drosophila sequences are indicated with the prefix "dme."

Table 1: Human, Mouse and Rat microRNA and anti-microRNA sequences.

microRNA name	microRNA sequence (5' to 3')	Anti-microRNA molecule sequence (5' to 3')
hsa-miR-100	AACCCGUAGAUCCGAACUUGUG	CACAAGUUCGGAUCUACGGGUU
hsa-miR-103	AGCAGCAUUGUACAGGGCUAUG	CAUAGCCCUGUACAAUGCUGCU
hsa-miR-105-5p	UCAA AUGCUCAGACUCCUGUGG	CCACAGGAGUCUGAGCAUUUGA
hsa-miR-106a	AAAAGUGCUUACAGUGCAGGUA	UACCUGCACUGUAAGCACUUUU
hsa-miR-106b	UAAAGUGCUGACAGUGCAGUA	UAUCUGCACUGUCAGCACUUUA
hsa-miR-107	AGCAGCAUUGUACAGGGCUAUC	GAUAGCCCUGUACAAUGCUGCU
hsa-miR-10b	UACCCUGUAGAACCGAAUUUGU	ACAAAUUCGGUUCUACAGGGUA
hsa-miR-128b	UCACAGUGAACCGGUCUCUUUC	GAAAGAGACCGGUUCACUGUGA
hsa-miR-130b	CAGUGCAAUGAUGAAAGGGCAU	AUGCCCUUUCAUCAUUGCACUG
hsa-miR-140-3p	UACCA CAGGGUAGAACCACGGA	UCCGUGGUUCUACCCUGUGGUA
hsa-miR-142-5p	CCCAUAAAGUAGAAAGCACUAC	GUAGUGCUUUCUACUUUAUGGG
hsa-miR-151-5p	UCGAGGAGCUCACAGUCUAGUA	UACUAGACUGUGAGCUCUCCGA
hsa-miR-155	UUAAUGCUAAUCGUGAUAGGGG	CCCCUAUCACGAUUAGCAUUA
hsa-miR-181a	AACAUUCAACGCUGUCGGUGAG	CUCACCGACAGCGUUGAAUGUU
hsa-miR-181b	AACAUUCAUUGCUGUCGGUGGG	CCCACCGACAGCAAUGAAUGUU
hsa-miR-181c	AACAUUCAACCUGUCGGUGAGU	ACUCACCGACAGGUUGAAUGUU
hsa-miR-182	UUUGGCAAUGGUAGAACUCACA	UGUGAGUUCUACCAUUGCCAAA
hsa-miR-183	UAUGGCACUGGUAGAAUUCACU	AGUGAAUUCUACCAGUGCCAU
hsa-miR-184	UGGACGGAGAACUGAUAAAGGGU	ACCCUUAUCAGUUCUCCGUCCA
hsa-miR-185	UGGAGAGAAAGGCAGUUCUGA	UCAGGAACUGCCUUUCUCUCCA
hsa-miR-186	CAAAGAAUUCUCCUUUUGGGCU	AGCCCAAAGGAGAAUUCUUUG
hsa-miR-187	UCGUGUCUUGUGUUGCAGCCGG	CCGGCUGCAACACAAGACACGA
hsa-miR-188-3p	CUCCCACAUGCAGGGUUUGCAG	CUGCAAACCCUGCAUGUGGGAG
hsa-miR-188-5p	CAUCCCUUGCAUGGUGGAGGGU	ACCCUCCACCAUGCAAGGGAUG
hsa-miR-189	GUGCCUACUGAGCUGAUUUCAG	CUGAUUUCAGCUCAGUAGGCAC
hsa-miR-190	UGAU AUGUUUGAUUAUUAAGGU	ACCUAUUAUUAUCAAUAUUA
hsa-miR-191	CAACGGAAUCCCAAAGCAGCU	AGCUGCUUUUGGGAUUCGGUUG
hsa-miR-192	CUGACCUAUGAAUUGACAGCCA	UGGCUGUCAAUUCAUAGGUCAG
hsa-miR-193-3p	AACUGGCCUACAAAGUCCCAGU	ACUGGGACUUUGUAGGCCAGUU
hsa-miR-193-5p	UGGGUCUUUGCGGGCAAGAUGA	UCAUCUUGCCCGCAAAGACCCA
hsa-miR-194	UGUAA CAGCAACUCCAUGUGGA	UCCACAUGGAGUUGCUGUUACA
hsa-miR-195	UAGCAGCACAGAAAUUUGGCA	UGCCAAUAUUUCUGUGCUGCUA
hsa-miR-196	UAGGUAGUUUCAUGUUGUUGGG	CCCAACAACAUGAAACUACCUA
hsa-miR-197	UUCACCACCUUCUCCACCCAGC	GCUGGGUGGAGAAGGUGGUGAA
hsa-miR-198	GGUCCAGAGGGGAGAUAGGUUC	GAACCUAUCUCCCCUCUGGACC
hsa-miR-199a-3p	ACAGUAGUCUGCACAUUGGUUA	UAACCAAUGUGCAGACUACUGU
hsa-miR-199a-5p	CCCAGUGUUCAGACUACCUGUU	AACAGGUAGUCUGAACACUGGG

microRNA name	microRNA sequence (5' to 3')	Anti-microRNA molecule sequence (5' to 3')
hsa-miR-199b	CCCAGUGUUUAGACUAUCUGUU	AACAGAUAGUCUAAACACUGGG
hsa-miR-200a	U AACACUGUCUGGUAACGAUGU	ACAUCGUUACCAGACAGUGUUA
hsa-miR-200b	CUCUAAUACUGCCUGGUAUAUGA	UCAUUACCAGGCAGUAUUAGAG
hsa-miR-200c	AAUACUGCCGGGUAAUGAUGGA	UCCAUCAUUACCCGGCAGUAUU
hsa-miR-203	GUGAAAUGUUUAGGACCACUAG	CUAGUGGUCCUAAACAUUUCAC
hsa-miR-204	UUCCCUUUGUCAUCCUAUGCCU	AGGCAUAGGAUGACAAAGGGAA
hsa-miR-205	UCCUUCAUUCCACCGGAGUCUG	CAGACUCCGGUGGAAUGAAGGA
hsa-miR-206	UGGAAUGUAAGGAAGUGUGUGG	CCACACACUCCCUUACAUCCA
hsa-miR-208	AUAAGACGAGCAA AAAGCUUGU	ACAAGCUUUUUGCUCGUCUUAU
hsa-miR-210	CUGUGCGUGUGACAGCGGCUGA	UCAGCCGCUGUCACACGCACAG
hsa-miR-211	UUCCCUUUGUCAUCCUUCGCCU	AGGCGAAGGAUGACAAAGGGAA
hsa-miR-212	U AACAGUCUCCAGUCACGGCCA	UGGCCGUGACUGGAGACUGUUA
hsa-miR-213	ACCAUCGACCGUUGAUUGUACC	GGUACAAUCAACGGUCGAUGGU
hsa-miR-214	ACAGCAGGCACAGACAGGCAGU	ACUGCCUGUCUGUGCCUGCUGU
hsa-miR-215	AUGACCUAUGAAUUGACAGACA	UGUCUGUCAAUUCAUAGGUCAU
hsa-miR-216	UAAUCUCAGCUGGCAACUGUGA	UCACAGUUGCCAGCUGAGAUUA
hsa-miR-217	UACUGCAUCAGGAACUGAUUGG	CCAAUCAGUUCUGAUGCAGUA
hsa-miR-218	UUGUGCUUGAUCUAACCAUGUG	CACAUGGUUAGAUAAGCACAA
hsa-miR-219	UGAUUGUCCAAACGCAAUUCUU	AAGAAUUGCGUUUGGACAAUCA
hsa-miR-220	CCACACCGUAUCUGACACUUUG	CAAAGUGUCAGAUACGGUGUGG
hsa-miR-221	AGCUACAUUGUCUGCUGGGUUU	AAACCCAGCAGACAAUGUAGCU
hsa-miR-222	AGCUACAUCUGGCUACUGGGUC	GACCCAGUAGCCAGAUGUAGCU
hsa-miR-223	UGUCAGUUUGUCAAAUACCCCA	UGGGGUAAUUUGACAAACUGACA
hsa-miR-224	CAAGUCACUAGUGGUUCCGUUU	AAACGGAACCAUAGUGACUUG
hsa-miR-28-5p	AAGGAGCUCACAGUCUAUUGAG	CUCAAUAGACUGUGAGCUCCUU
hsa-miR-290	CUCAAACUGUGGGGGGCACUUUC	GAAAGUGCCCCCACAGUUUGAG
hsa-miR-296	AGGGCCCCCCCCUCAUCCUGUU	AACAGGAUUGAGGGGGGGCCCU
hsa-miR-299	UGGUUUACCGUCCCAUAUACAU	AUGUAUGUGGGACGGUAAACCA
hsa-miR-301	CAGUGCAAUAGUAUUGUCAAG	CUUUGACAAUACUAUUGCACUG
hsa-miR-302	UAAGUGCUUCCAUGUUUUGGUG	CACCAAACAUGGAAGCACUUA
hsa-miR-30e	UGUAAACAUCUUGACUGGAAG	CUUCCAGUCAAGGAUGUUUACA
hsa-miR-320	AAAAGCUGGGUUGAGAGGGCGA	UCGCCCUCUCAACCCAGCUUUU
hsa-miR-321	UAAGCCAGGGAUUGUGGGUUCG	CGAACCCACAAUCCCUGGCUUA
hsa-miR-322	AAACAUGAAUUGCUGCUGUAUC	GAUACAGCAGCAAUUCAUGUUU
hsa-miR-323	GCACAUUACACGGUCGACCUCU	AGAGGUCGACCGUGUAAUGUGC
hsa-miR-324-3p	CCACUGCCCCAGGUGCUGCUGG	CCAGCAGCACCUGGGGGCAGUGG
hsa-miR-324-5p	CGCAUCCCCUAGGGCAUUGGUG	CACCAAUGCCCUGGGGAUGCG
hsa-miR-326	CCUCUGGGCCCCUUCUCCAGCC	GGCUGGAGGAAGGGCCCAGAGG
hsa-miR-328	CUGGCCCUUCUGCCCUUCCGU	ACGGAAGGGCAGAGAGGGCCAG
hsa-miR-329	AACACACCCAGCUAACC UUUUU	AAAAGGUUAGCUGGGUGUGUU
hsa-miR-34a	UGGCAGUGUCUAGCUGGUUGU	ACAACCAGCUAAGACACUGCCA
hsa-miR-34b	AGGCAGUGUCAUAGCUGAUUG	CAAUCAGCUAAUGACACUGCCU
hsa-miR-34c	AGGCAGUGUAGUAGCUGAUUG	CAAUCAGCUAACUACACUGCCU
hsa-miR-92	UAUUGCACUUGUCCCGGCCUGU	ACAGGCCGGGACAAGUGCAAUA
hsa-miR-93	AAAGUGCUGUUCGUGCAGGUAG	CUACCUGCACGAACAGCACUUU
hsa-miR-95	UUCAACGGGUAAUUUAUUGAGCA	UGCUCAAUAAAUAACCGUUGAA
hsa-miR-96	UUUGGCACUAGCACAUUUUUGC	GCAAAA AUGUGCUAGUGCCAAA
hsa-miR-98	UGAGGUAGUAAGUUGUAUUGUU	AACAAUACAACUUACUACCUCA
mmu-miR-106a	CAAAGUGCUAACAGUGCAGGUA	UACCUGCACUGUUAGCACUUUG
mmu-miR-10b	CCCUGUAGAACCGAAUUUUGUGU	ACACAAAUUCGGUUCUACAGGG
mmu-miR-135b	UAUGGCUUUUCAUUCCUAUGUG	CACAUAGGAAUGAAAAGCCAUA

microRNA name	microRNA sequence (5' to 3')	Anti-microRNA molecule sequence (5' to 3')
mmu-miR-148b	UCAGUGCAUCACAGAACUUUGU	ACAAAGUUCUGUGAUGCACUGA
mmu-miR-151-3p	CUAGACUGAGGCUCCUUGAGGA	UCCUCAAGGAGCCUCAGUCUAG
mmu-miR-155	UUA AUGCUAAUUGUGAUAGGGG	CCCCUAUCACAAUUAGCAUUA
mmu-miR-199b	CCCAGUGUUUAGACUACCUGUU	AACAGGUAGUCUAAACACUGGG
mmu-miR-200b	UAAUACUGCCUGGUA AUGAUGA	UCAUCAUUACCAGGCAGUAUUA
mmu-miR-203	UGAAAUGUUUAGGAC CACUAGA	UCUAGUGGUCCUAAACAUUUCA
mmu-miR-211	UCCCCUUUGUCAUCCUUUGCCU	AGGCAAAGGAUGACAAAGGGAA
mmu-miR-217	UACUGCAUCAGGAACUGACUGG	CCAGUCAGUUC CUGAUGCAGUA
mmu-miR-224	UAAGUCACUAGUGGUUCCGUUU	AAACGGAAC CACUAGUGACUUA
mmu-miR-28-3p	CACUAGAUUGUGAGCUGCUGGA	UCCAGCAGCUCACAAUCUAGUG
mmu-miR-290	CUCAAACUAUGGGGG CACUUUU	AAAAGUGCCCCCAUAGUUUGAG
mmu-miR-291-3p	AAAGUGCUUCCACUUUGUGUGC	GCACACAAAGUGGAAGCACUUU
mmu-miR-291-5p	CAUCAAGUGGAGGC CCUCUCU	AGAGAGGGCCUCCACUUUGAUG
mmu-miR-292-3p	AAGUGCCGCCAGGUUUUGAGUG	CACUCAAAACCUGGCGGCACUU
mmu-miR-292-5p	ACUCAAACUGGGGGCUCUUUUG	CAAAGAGCCCCCAGUUUGAGU
mmu-miR-293	AGUGCCGCAGAGUUUGUAGUGU	ACACUACAAACUCUGCGGCACU
mmu-miR-294	AAAGUGCUUCCCUUUUGUGUGU	ACACACAAAAGGGAAGCACUUU
mmu-miR-295	AAAGUGCUACUACUUUUGAGUC	GACUCAAAAGUAGUAGCACUUU
mmu-miR-297	AUGUAUGUGUGCAUGUGCAUGU	ACAUGCACAUGCACACAUACAU
mmu-miR-298	GGCAGAGGAGGGCUGUUCUUC	GGAAGAACAGCCCUCCUCUGCC
mmu-miR-300	UAUGCAAGGGCAAGCUCUCUUC	GAAGAGAGCUUGCCCUUGCAUA
mmu-miR-31	AGGCAAGAUGCUGGCAUAGCUG	CAGCUAUGCCAGCAUCUUGCCU
mmu-miR-322	AAACAUGAAGCGCUG CAACACC	GGUGUUGCAGCGCUUCAUGUUU
mmu-miR-325	CCUAGUAGGUGCUCAGUAAGUG	CACUUACUGAGCACCUACUAGG
mmu-miR-326	CCUCUGGGCCCUUCCUCCAGUC	GACUGGAGGAAGGGCC CAGAGG
mmu-miR-330	GCAAAGCACAGGGCCUGCAGAG	CUCUGCAGGCCCUUGUGCUUUGC
mmu-miR-331	GCCCCUGGGCCUAUC CUAGAAC	GUUCUAGGAUAGGCC CAGGGGC
mmu-miR-337	UUCAGCUCCUAUAUG AUGCCUU	AAGGCAUCAUAUAGGAGCUGAA
mmu-miR-338	UCCAGCAUCAGUGAUUUUGUUG	CAACAAAUCACUGAUGCUGGA
mmu-miR-339	UCCUGUCCUCCAGGAGCUCAC	GUGAGCUCCUGGAGGACAGGGA
mmu-miR-340	UCCGUCUCAGUUACUUUAUAGC	GCUAUAAAGUAACUGAGACGGA
mmu-miR-341	UCGAUCGGUCGGUCGGUCAGUC	GACUGACCGACCGACCGAUCCA
mmu-miR-342	UCUCACACAGAAUUCGCACCCG	CGGGUGCGAUUUCUGUGUGAGA
mmu-miR-344	UGAUCUAGCCAAAGCCUGACUG	CAGUCAGGCUUUGGCUAGAUA
mmu-miR-345	UGCUGACCCCUAGUC CAGUGCU	AGCACUGGACUAGGGGUCAGCA
mmu-miR-346	UGUCUGCCCGAGUGCCUGCCUC	GAGGCAGGCACUCGGGCAGACA
mmu-miR-34b	UAGGCAGUGUAAUUAGCUGAUU	AAUCAGCUAAUUAACACUGCCUA
mmu-miR-350	UUCACAAAGCCCAUACACUUUC	GAAAGUGUAUGGGCUUUGUGAA
mmu-miR-351	UCCCUGAGGAGCCCUUGAGCC	GGCUCAAAGGGCUCCUCAGGGA
mmu-miR-7b	UGGAAGACUUGUGAUUUUGUUG	CAACAAAUCACAAGUCUCCA
mmu-miR-92	UAUUGCACUUGUCCCGGCCUGA	UCAGGCCGGGACAAGUGCAAUA
mmu-miR-93	CAAAGUGCUGUUCGUGCAGGUA	UACCUGCACGAACAGCACUUUG
rno-miR-327	CCUUGAGGGGCAUGAGGGUAGU	ACUACCCUCAUGCCCCUCAAGG
rno-miR-333	GUGGUGUGCUAGUUACUUUUGG	CCAAAAGUAACUAGCACACCAC
rno-miR-335	UCAAGAGCAAUAACGAAAAAUG	CAUUUUUCGUUAUUGCUCUUGA
rno-miR-336	UCACCCUCCAUUAUCUAGUCUC	GAGACUAGAU AUGGAAGGGUGA
rno-miR-343	UCUCCCUCCGUGUGCC CAGUAU	AUACUGGGCACACGGAGGGAGA
rno-miR-347	UGUCCCUUGGGUCGCC CAGCU	AGCUGGGCGACCCAGAGGGACA
rno-miR-349	CAGCCCUUGCUGUCUUAACCUCU	AGAGGUUAAGACAGCAGGGCUG
rno-miR-352	AGAGUAGUAGGUUGCAUAGUAC	GUACUAUGCAACCUACUACUCU

Table 2: Novel Human microRNA and anti-microRNA sequences.

microRNA name	microRNA sequence (5' to 3')	Anti-microRNA molecule sequence (5' to 3')
hsa-miR-361	UUAUCAGAAUCUCCAGGGGUAC	GUACCCCUUGGAGAUUCUGAUAA
hsa-miR-362	AAUCCUUGGAACCUAGGUGUGA	UCACACCUAGGUUCCAAGGAUU
hsa-miR-363	AUUGCACGGUAUCCAUCUGUAA	UUACAGAUGGAUACCGUGCAAU
hsa-miR-364	CGGCGGGGACGGCGAUUGGUCC	GGACCAAUCGCCGUCCCCGCCG
hsa-miR-365	UAAUGCCCCUAAAAAUCCUUAU	AUAAGGAUUUUUAGGGGGCAUUA
hsa-miR-366	UAACUGGUUGAACAACUGAACC	GGUUCAGUUGUUCAACCAGUUA

Table 3: C. elegans microRNA and anti-microRNA sequences.

microRNA name	microRNA sequence (5' to 3')	Anti-microRNA molecule sequence (5' to 3')
Cel-let-7	UGAGGUAGUAGGUUGUAUAGUU	AACUAUACAACCUACUACCUCA
Cel-lin-4	UCCCUGAGACCUCAAGUGUGAG	CUCACACUUGAGGUCUCAGGGA
Cel-miR-1	UGGAAUGUAAAGAAGUAUGUAG	CUACAUACUUCUUUACAUAUCCA
Cel-miR-2	UAUCACAGCCAGCUUUGAUGUG	CACAUCAAAGCUGGCUGUGAUA
Cel-miR-34	AGGCAGUGUGGUUAGCUGGUUG	CAACCAGCUAACCACACUGCCU
Cel-miR-35	UCACCGGGUGGAAACUAGCAGU	ACUGCUAGUUUCCACCCGGUGA
Cel-miR-36	UCACCGGGUGAAAAUUCGCAUG	CAUGCAGAAUUUUCACCCGGUGA
Cel-miR-37	UCACCGGGUGAACACUUGCAGU	ACUGCAAGUGUUCACCCGGUGA
Cel-miR-38	UCACCGGGGAGAAAAACUGGAGU	ACUCCAGUUUUUCUCCCGGUGA
Cel-miR-39	UCACCGGGUGUAAAUCAGCUUG	CAAGCUGAUUUACACCCGGUGA
Cel-miR-40	UCACCGGGUGUACAUCAGCUAA	UUAGCUGAUGUACACCCGGUGA
Cel-miR-41	UCACCGGGUGAAAAAUCACCUA	UAGGUGAUUUUUCACCCGGUGA
Cel-miR-42	CACCGGGUUAACAUCUACAGAG	CUCUGUAGAUGUUUAACCCGGUG
Cel-miR-43	UAUCACAGUUUACUUGCUGUCG	CGACAGCAAGUAAACUGUGAUA
Cel-miR-44	UGACUAGAGACACAUCAGCUU	AAGCUGAAUGUGUCUCUAGUCA
Cel-miR-45	UGACUAGAGACACAUCAGCUU	AAGCUGAAUGUGUCUCUAGUCA
Cel-miR-46	UGUCAUGGAGUCGCUCUCUUA	UGAAGAGAGCGACUCCAUGACA
Cel-miR-47	UGUCAUGGAGGCGCUCUCUUA	UGAAGAGAGCGCCUCCAUGACA
Cel-miR-48	UGAGGUAGGCUCAGUAGAUGCG	CGCAUCUACUGAGCCUACCUCA
Cel-miR-49	AAGCACCACGAGAAGCUGCAGA	UCUGCAGCUUCUCGUGGUGCUU
Cel-miR-50	UGAUUAUGUCUGGUUAUUCUUGGG	CCCAAGAAUACCAGACAUUAUCA
Cel-miR-51	UACCCGUAGCUCCUAUCCAUGU	ACAUGGAUAGGAGCUACGGGUA
Cel-miR-52	CACCCGUACAUAUGUUUCCGUG	CACGGAAACAUAUGUACGGGUG
Cel-miR-53	CACCCGUACAUAUGUUUCCGUG	CACGGAAACAAUUGUACGGGUG
Cel-miR-54	UACCCGUAAUCUUAUAUAUCCG	CGGAUUAUGAAGAUUACGGGUA
Cel-miR-55	UACCCGUAAUAGUUUUCUGCUGA	UCAGCAGAAACUUAUACGGGUA
Cel-miR-56	UACCCGUAAUGUUUCCGCUGAG	CUCAGCGGAAACAUAUACGGGUA
Cel-miR-57	UACCCUGUAGAUCGAGCUGUGU	ACACAGCUCGAUCUACAGGGUA
Cel-miR-58	UGAGAUCGUUCAGUACGGCAAU	AUUGCCGUACUGAACGAUCUCA
Cel-miR-59	UCGAAUCGUUUUAUCAGGAUGAU	AUCAUCCUGAUAAACGAUUCGA
Cel-miR-60	UAUUAUGCACAUUUUCUAGUUC	GAACUAGAAAAUGUGCAUAAUA
Cel-miR-61	UGACUAGAACCGUUAUCUACUCU	AGAUGAGUAAACGGUUCUAGUCA
Cel-miR-62	UGAUUAUGUAAUCUAGCUUACAG	CUGUAAGCUAGAUUACAUAUCA
Cel-miR-63	AUGACACUGAAGCGAGUUGGAA	UUCCAACUCGCUUCAGUGUCAU

microRNA name	microRNA sequence (5' to 3')	Anti-microRNA molecule sequence (5' to 3')
Cel-miR-64	UAUGACACUGAAGCGUUACCGA	UCGGUAAACGCUUCAGUGUCAUA
Cel-miR-65	UAUGACACUGAAGCGUAACCGA	UCGGUUACGCUUCAGUGUCAUA
Cel-miR-66	CAUGACACUGAUUAGGGAUGUG	CACAUCCCUAAUCAGUGUCAUG
Cel-miR-67	UCACAACCUCCUAGAAAGAGUA	UACUCUUUCUAGGAGGUUGUGA
Cel-miR-68	UCGAAGACUCAAAGUGUAGAC	GUCUACACUUUUUGAGUCUUCGA
Cel-miR-69	UCGAAAAUUAAAAAGUGUAGAA	UUCUACACUUUUUAAUUUUUCGA
Cel-miR-70	UAAUACGUCGUUGGUGUUUCCA	UGGAAACACCAACGACGUUUUA
Cel-miR-71	UGAAAGACAUGGGUAGUGAACG	CGUUCACUACCCAUGUCUUUCA
Cel-miR-72	AGGCAAGAUGUUGGCAUAGCUG	CAGCUAUGCCAACAUCUUGCCU
Cel-miR-73	UGGCAAGAUGUAGGCAGUUCAG	CUGAACUGCCUACAUCUUGCCA
Cel-miR-74	UGGCAAGAAAUGGCAGUCUACA	UGUAGACUGCCAUUUUCUUGCCA
Cel-miR-75	UUAAGCUACCAACCGGCUUCA	UGAAGCCGGUUGGUAGCUUUAA
Cel-miR-76	UUCGUUGUUGAUGAAGCCUUGA	UCAAGGCUUCAUCAACAACGAA
Cel-miR-77	UUCAUCAGGCCAUAGCUGUCCA	UGGACAGCUAUGGCCUGAUGAA
Cel-miR-78	UGGAGGCCUGGUUGUUUGUGCU	AGCACAACAACCAAGGCCUCCA
Cel-miR-79	AUAAAGCUAGGUUACCAAAGCU	AGCUUUGGUAACCUAGCUUUUAU
Cel-miR-227	AGCUUUCGACAUGAUUCUGAAC	GUUCAGAAUCAUGUCGAAAGCU
Cel-miR-80	UGAGAUCAUUAGUUGAAAGCCG	CGGCUUUCACUAAUGAUCUCA
Cel-miR-81	UGAGAUCAUUCGUGAAAGCUAGU	ACUAGCUUUCACGAUGAUCUCA
Cel-miR-82	UGAGAUCAUUCGUGAAAGCCAGU	ACUGGCUUUCACGAUGAUCUCA
Cel-miR-83	UAGCACCAUAUAAAUUCAGUAA	UUACUGAAUUUAUAUGGUGCUA
Cel-miR-84	UGAGGUAGUAUGUAAUAUUGUA	UACAAUAUUACAUAUACCUCA
Cel-miR-85	UACAAAGUAUUUGAAAAGUCGU	ACGACUUUUCAAUAUACUUUGUA
Cel-miR-86	UAAGUGAAUGCUUUGCCACAGU	ACUGUGGCAAAGCAUUCACUUA
Cel-miR-87	GUGAGCAAAGUUUCAGGUGUGC	GCACACCUGAAACUUUGCUCAC
Cel-miR-90	UGAUAUGUUGUUUGAAUGCCCC	GGGGCAUUCAAACAACAUAUCA
Cel-miR-124	UAAGGCACGCGGUGAAUGCCAC	GUGGCAUUCACCGCGUGCCUUA
Cel-miR-228	AAUGGCACUGCAUGAAUUCACG	CGUGAAUUC AUGCAGUGCCAUU
Cel-miR-229	AAUGACACUGGUUAUCUUUUCC	GGAAAAGAUAAACCAGUGUCAUU
Cel-miR-230	GUUUUAGUUGUGCGACCAGGAG	CUCCUGGUCGCACAACUAAUAC
Cel-miR-231	UAAGCUCGUGAUCAACAGGCAG	CUGCCUGUUGAUACAGAGCUUA
Cel-miR-232	UAAAUGCAUCUUAACUGCGGUG	CACCGCAGUUAAGAUGCAUUUA
Cel-miR-233	UUGAGCAAUGCGCAUGUGCGGG	CCCGCACAUGCGCAUUGCUCAA
Cel-miR-234	UUUUUGCUCGAGAAUACCCUUU	AAAGGGUAUUCUCGAGCAAUAA
Cel-miR-235	UAUUGCACUCUCCCCGGCCUGA	UCAGGCCGGGGAGAGUGCAAUA
Cel-miR-236	UAAUACUGUCAGGUAAUGACGC	GCGUCAUUACCUGACAGUAUUA
Cel-miR-237	UCCUGAGAAUUCUCGAACAGC	GCUGUUCGAGAAUUCUCAGGGA
Cel-miR-238	UUUGUACUCCGAUGCCAUCUAG	CUGAAUGGCAUCGGAGUACAAA
Cel-miR-239a	UUUGUACUACACAAAGUACUG	CAGUACCUAUGUGUAGUACAAA
Cel-miR-239b	UUUGUACUACACAAAGUACUG	CAGUACUUUUGUGUAGUACAAA
Cel-miR-240	UACUGGCCCCCAAUCUUCGCU	AGCGAAGAUUUGGGGGGCCAGUA
Cel-miR-241	UGAGGUAGGUGCGAGAAUGAC	GUCAUUUCUCGCACCUACCUCA
Cel-miR-242	UUGCGUAGGCCUUUGCUUCGAG	CUCGAAGCAAAGGCCUACGCAA
Cel-miR-243	CGGUACGAUCGCGGCGGGAUUA	AUAUCCCGCCGCGAUUCGUACCG
Cel-miR-244	UCUUUGGUUGUACAAAGUGGUA	UACCACUUUGUACAACCAAAGA
Cel-miR-245	AUUGGUCCCCUCCAAGUAGCUC	GAGCUACUUGGAGGGGACCAAU
Cel-miR-246	UUACAUGUUUCGGGUAGGAGCU	AGCUCCUACCCGAAACAUGUAA
Cel-miR-247	UGACUAGAGCCUAUUCUCUUCU	AGAAGAGAAUAGGCUCUAGUCA
Cel-miR-248	UACACGUGCACGGAUAACGCUC	GAGCGUUAUCCGUGCACGUGUA
Cel-miR-249	UCACAGGACUUUUGAGCGUUGC	GCAACGCUCAAAAGUCCUGUGA
Cel-miR-250	UCACAGUCAACUGUUGGCAUGG	CCAUGCCAACAGUUGACUGUGA

microRNA name	microRNA sequence (5' to 3')	Anti-microRNA molecule sequence (5' to 3')
Cel-miR-251	UUAAGUAGUGGUGCCGCUCUUA	UAAGAGCGGCACCACUACUUA
Cel-miR-252	UAAGUAGUAGUGCCGCAGGUAA	UUACCUGCGGCACUACUACUUA
Cel-miR-253	CACACCUCACUAAACACUGACCA	UGGUCAGUGUUAGUGAGGUGUG
Cel-miR-254	UGCAAUUCUUUCGCGACUGUAG	CUACAGUCGCGAAAGAUUUUGCA
Cel-miR-256	UGGAAUGCAUAGAAGACUGUAC	GUACAGUCUUCUAUGCAUUCUUA
Cel-miR-257	GAGUAUCAGGAGUACCCAGUGA	UCACUGGGUACUCCUGAUACUC
Cel-miR-258	GGUUUUGAGAGGAAUCCUUUUA	UAAAAGGAUUCUCUCAAAACC
Cel-miR-259	AGUAAAUCUCAUCCUAAUCUGG	CCAGAUUAGGAUGAGAUUUACU
Cel-miR-260	GUGAUGUCGAACUCUUGUAGGA	UCCUACAAGAGUUCGACAUCAC
Cel-miR-261	UAGCUUUUUAGUUUUUACCGGUG	CACCGUGAAAACUAAAAAGCUA
Cel-miR-262	GUUUCUCGAUGUUUUUCUGAUAC	GUAUCAGAAAACAUCGAGAAAC
Cel-miR-264	GGCGGGUGGUUGUUGUUAUGGG	CCCAUAACAACAACCACCCGCC
Cel-miR-265	UGAGGGAGGAAGGGUGGUUUUU	AAAUACCACCCUUCUCCCUCA
Cel-miR-266	AGGCAAGACUUUGGCAAAGCUU	AAGCUUUGCCAAAGUCUUGCCU
Cel-miR-267	CCCGUGAAGUGUCUGCUGCAAU	AUUGCAGCAGACACUUCACGGG
Cel-miR-268	GGCAAGAAUUAGAAGCAGUUUG	CAAACUGCUUCUAAUUCUUGCC
Cel-miR-269	GGCAAGACUCUGGCAAAACUUG	CAAGUUUUUGCCAGAGUCUUGCC
Cel-miR-270	GGCAUGAUGUAGCAGUGGAGAU	AUCUCCACUGCUACAUCUUGCC
Cel-miR-271	UCGCCGGGUGGGAAAGCAUUCG	CGAUGCUUUCUCCACCCGGCGA
Cel-miR-272	UGUAGGCAUGGGUGUUUGGAAG	CUUCCAAACACCCAUGCCUACA
Cel-miR-273	UGCCCGUACUGUGUCGGCUGCU	AGCAGCCGACACAGUACGGGCA

Table 4: Drosophila microRNA and anti-microRNA sequences.

microRNA name	microRNA sequence (5' to 3')	Anti-microRNA molecule sequence (5' to 3')
Dme-miR-263a	GUUAAUGGCACUGGAAGAAUUC	GAAUUCUUC CAGUGCCA UUAAC
Dme-miR-184	UGGACGGAGAACUGAU AAGGGC	GCCCUUAUCAGUUCUCCGUCCA
Dme-miR-274	UUUUGUGACCGACACUAACGGG	CCCGUUAGUGUCGGUCACAAA
Dme-miR-275	UCAGGUACCUGAAGUAGCGCGC	GCGCGCUACUUCAGGUACCUGA
Dme-miR-92a	CAUUGCACUUGUCCCGGCCUAU	AUAGGCCGGGACAAGUGCAAUG
Dme-miR-219	UGAUUGUCCAAACGCAAUUCUU	AAGAAUUGCGUUUGGACAAUCA
Dme-miR-276a	UAGGAACUUCAUACCGUGCUCU	AGAGCACGGUAUGAAGUUCUA
Dme-miR-277	UAAAUUGCACUAUCUGGUACGAC	GUCGUACCAGAUAGUGCAUUA
Dme-miR-278	UCGGUGGGACUUUCGUCCGUUU	AAACGGACGAAAGUCCCACCGA
Dme-miR-133	UUGGUCCCCUUC AACCAGCUGU	ACAGCUGGUUGAAGGGGACCAA
Dme-miR-279	UGACUAGA UCCACACUCAUUA	UUAAUGAGUGUGGAUCUAGUCA
Dme-miR-33	AGGUGCAUUGUAGUCGCAUUGU	ACAAUGCGACUACAAUGCACC
Dme-miR-280	UGUAUUUACGUUGCAUAUGAAA	UUUCAUAUGCAACGUAAAUACA
Dme-miR-281	UGUCAUGGAAUUGCUCUCUUUG	CAAAGAGAGCAAUUC CAUGACA
Dme-miR-282	AAUCUAGCCUCUACUAGGCUUU	AAAGCCUAGUAGAGGCUAGAUU
Dme-miR-283	UAAAUUAUCAGCUGGUAAUUCUG	CAGAAUUAACCAGCUGAUAUUA
Dme-miR-284	UGAAGUCAGCAACUUGAUUCCA	UGGAAUCAAGUUGCUGACUUA
Dme-miR-34	UGGCAGUGUGGUUAGCUGGUUG	CAACCAGCUAACCACACUGCCA
Dme-miR-124	UAAGGCACGCGGUGAAUGCCAA	UUGGCAUUCACCGCGUGCCUUA
Dme-miR-79	UAAAGCUAGAUUACCAAAGCAU	AUGCUUUGGUAAUUCUAGCUUA
Dme-miR-276b	UAGGAACUUA AUACCGUGCUCU	AGAGCACGGUAUUAAGUUCUA
Dme-miR-210	UUGUGCGUGUGACAGCGGCUAU	AUAGCCGCUGUCACACGCACAA
Dme-miR-285	UAGCACCAUUCGAAAUCAGUGC	GCACUGAUUUCGAAUGGUGCUA
Dme-miR-100	AACCCGUAAAUCCGAACUUGUG	CACAAGUUCGGAUUAACGGGUU
Dme-miR-92b	AAUUGCACUAGUCCCGGCCUGC	GCAGGCCGGGACUAGUGCAAUU
Dme-miR-286	UGACUAGACCGAACACUCGUGC	GCACGAGUGUUCGGUCUAGUCA
Dme-miR-287	UGUGUUGAAAAUCGUUUGCACG	CGUGCAAACGAUUUUAACACA
Dme-miR-87	UUGAGCAAAAUUUCAGGUGUGU	ACACACCUGAAAUUUUGCUCAA
Dme-miR-263b	CUUGGCACUGGGAGAAUUCACA	UGUGAAUUCUCC CAGUGCCAAG
Dme-miR-288	UUUCAUGUCGAUUUUAUUAU	AUGAAAUGAAAUCGACAUGAAA
Dme-miR-289	UAAAUUAUUUAAGUGGAGCCUGC	GCAGGCUCCACUUA AAUAUUA
Dme-bantam	UGAGAUCAUUUUGAAAGCUGAU	AUCAGCUUUC AAAAUGAUCUCA
Dme-miR-303	UUUAGGUUUCACAGGAAACUGG	CCAGUUUCCUGUGAAACC UAAA
Dme-miR-31b	UGGCAAGAUGUCGGAAUAGCUG	CAGCUAUUCCGACAUCUUGCCA
Dme-miR-304	UAAUCUCAAUUUUGUAAAUGUGA	UCACAUUUUACAAAUUGAGAUUA
Dme-miR-305	AUUGUACUUCAU CAGGUGCUCU	AGAGCACCUGAUGAAGUACAAU
Dme-miR-9c	UCUUUGGUUAUUCUAGCUGUAGA	UCUACAGCUAGAAUACCAAAGA
Dme-miR-306	UCAGGUACUUA GUGACUCUCAA	UUGAGAGUCACUAAGUACCUGA
Dme-miR-9b	UCUUUGGUGAUUUUAGCUGUAU	AUACAGCUAAA AUACCAAAGA
Dme-miR-125	UCCCUGAGACCCUAACUUGUGA	UCACAAGUUAGGGUCUCAGGGA
Dme-miR-307	UCACAACCUCUUGAGUGAGCG	CGCUCACUCAAGGAGGUUGUGA
Dme-miR-308	AAUCACAGGAUUUAUCUGUGAG	CUCACAGUAUAAUCCUGUGAUU
dme-miR-31a	UGGCAAGAUGUCGGCAUAGCUG	CAGCUAUGCCGACAUCUUGCCA
dme-miR-309	GCACUGGGUAAAGUUUGUCCUA	UAGGACAAACUUUA CCCAGUGC
dme-miR-310	UAUUGCACACUUC CCGGCCUUU	AAAGGCCGGGAAGUGUGCAAUA
dme-miR-311	UAUUGCACAUUCACCGGCCUGA	UCAGGCCGGUGAAUGUGCAAUA
dme-miR-312	UAUUGCACUUGAGACGGCCUGA	UCAGGCCGUCUCAAGUGCAAUA
dme-miR-313	UAUUGCACUUUUCACAGCCCGA	UCGGGCUGUGAAAAGUGCAAUA
dme-miR-314	UAUUCGAGCCAAUAAGUUCGG	CCGAACUUAUUGGCUCGAAUA

microRNA name	microRNA sequence (5' to 3')	Anti-microRNA molecule sequence (5' to 3')
dme-miR-315	UUUUGAUUGUUGCUCAGAAAGC	GCUUUCUGAGCAACAAUCAAAA
dme-miR-316	UGUCUUUUUCCGCUUACUGGCG	CGCCAGUAAGCGGAAAAAGACA
dme-miR-317	UGAACACAGCUGGUGGUAUCCA	UGGAUACCACCAGCUGUGUUCA
dme-miR-318	UCACUGGGGCUUUGUUUAUCUCA	UGAGAUAAACAAAGCCCAGUGA
dme-miR-2c	UAUCACAGCCAGCUUUGAUGGG	CCCAUCAAAAGCUGGCUGUGAUA
Dme-miR-iab45p	ACGUAUACUGAAUGUAUCCUGA	UCAGGAUACAUUCAGUAUACGU
Dme-miR-iab43p	CGGUAUACCUUCAGUAUACGUA	UACGUAUACUGAAGGUAUACCG

EXAMPLES

Example 1: Materials and Methods

Oligonucleotide synthesis

MiR-21 were synthesized using 5'-silyl, 2'-ACE phosphoramidites (Dharmacon, Lafayette, CO, USA) on 0.2 μ mol synthesis columns using a modified ABI 394 synthesizer (Foster City, CA, USA) (Scaringe, Methods Enzymol. 317, 3-18 (2001) and Scaringe, Methods 23, 206-217 (2001)). The phosphate methyl group was removed by flushing the column with 2 ml of 0.2 M 2-carbamoyl-2-cyanoethylene-1,1-dithiolate trihydrate in DMF/water (98:2 v/v) for 30 min at room temperature. The reagent was removed and the column rinsed with 10 ml water followed by 10 ml acetonitrile. The oligonucleotide was cleaved and eluted from the solid support by flushing with 1.6 ml of 40% aqueous methylamine over 2 min, collected in a screwcap vial and incubated for 10 min at 55 °C. Subsequently, the base-treated oligonucleotide was dried down in an Eppendorf concentrator to remove methylamine and water. The residue was dissolved in sterile 2'-deprotection buffer (400 μ l of 100 mM acetate-TEMED, pH 3.8, for a 0.2 μ mol scale synthesis) and incubated for 30 minutes at 60 °C to remove the 2' ACE group. The oligoribonucleotide was precipitated from the acetate-TEMED solution by adding 24 μ l 5 M NaCl and 1.2 ml of absolute ethanol.

2'-O-Methyl oligoribonucleotides were synthesized using 5'-DMT, 2'-O-methyl phosphoramidites (Proligo, Hamburg, Germany) on 1 μ mol synthesis columns loaded with 3'-aminomodifier (TFA) C7 Icaa control pore glass support (Cherngen, MA, USA). The aminolinker was added in order to also use the oligonucleotides for conjugation to amino group

reactive reagents, such as biotin succinimidyl esters. The synthesis products were deprotected for 16 h at 55 °C in 30% aqueous ammonia and then precipitated by the addition of 12 ml absolute 1-butanol. The full-length product was then gel-purified using a denaturing 20% polyacrylamide gel. 2'-Deoxyoligonucleotides were prepared using 0.2 µmol scale synthesis and standard DNA synthesis reagents (Proligo, Hamburg, Germany).

The sequences of the 2'-O-methyl oligoribonucleotides were 5'-GUCAACAUCAGUCUGAUAAGCUAL (L, 3' aminolinker) for 2'-OMe miR-21, and 5'-AAGGCAAGCUGACCCUGAAGUL for EGFP 2'-OMe antisense, 5'-UGAAGUCCCAGUCGAACGGAAL for EGFP 2'-OMe reverse; the sequence of chimeric 2'-OMe/DNA oligonucleotides was 5'-GTCAACATCAGTCTGATAAGCTAGGCGL for 2'-deoxy miR-21 (underlined, 2'-OMe residues), and 5'-AAGGCAAGCTGACCCTGAAGTGGCGL for EGFP 2'-deoxy antisense.

The miR-21 cleavage substrate was prepared by PCR-based extension of the partially complementary synthetic DNA oligonucleotides 5'-GAACAATTGCTTTTACAGATGCACATATCGAGGTGAACATCACGTACGTCAACATCATCTGATAAGCTATCGGTTGGCAGAAGCTAT and 5'-GGCATAAAGAATTGAAGAGAGTTTTCACTGCATACGACGATTCTGTGATTTGTATTCAGCCCATATCGTTTCATAGCTTCTGCCAACCGA. The extended dsDNA was then used as template for a new PCR with primers 5'-TAATACGACTCACTATAGAACAATTGCTTTTACAG and 5'-ATTTAGGTGACACTATAGGCATAAAGAATTGAAGA to introduce the T7 and SP6 promoter sequences for in vitro transcription. The PCR product was ligated into pCR2.1-TOPO (Invitrogen). Plasmids isolated from sequence-verified clones were used as templates for PCR to produce sufficient template for run-off in vitro transcription reactions using phage RNA polymerases (Elbashir et al., EMBO 20, 6877-6888 (2001)). ³²P-Cap-labelling was performed as reported (Martinez et al., Cell 110, 563-574 (2002)).

Plasmids

Plasmids pEGFP-S-21 and pEGFP-A-21 were generated by T4 DNA ligation of preannealed oligodeoxynucleotides 5'-GGCCTCAACATCAGTCTGATAAGCTAGGTACCT

and 5'-GGCCAGGTACCTAGCTTATCAGACTGATGTTGA into NotI digested pEGFP-N-1 (Clontech). The plasmid pHcRed-C1 was from Clontech.

HeLa extracts and miR-21 quantification

HeLa cell extracts were prepared as described (Dignam et al., Nucleic Acid Res. 11 1475-1489 (1983)). 5×10^9 cells from HeLa suspension cultures were collected by centrifugation and washed with PBS (pH 7.4). The cell pellet (approx. 15 ml) was re-suspended in two times of its volume with 10mM KCl/1.5 mM $MgCl_2$ /0.5 mM dithiothreitol/10mM HEPES-KOH (pH 7.9) and homogenized by douncing. The nuclei were then removed by centrifugation of the cell lysate at 1000 g for 10 min. The supernatant was spun in an ultracentrifuge for 1 h at 10,5000 g to obtain the cytoplasmic S100 extract. The concentration of KCl of the S100 extract was subsequently raised to 100 mM by the addition of 1 M KCl. The extract was then supplemented with 10% glycerol and frozen in liquid nitrogen.

280 μ g of total RNA was isolated from 1 ml of S100 extract using the acidic guanidinium thiocyanate-phenol-chloroform extraction method (Chomczynski et al., Anal. Biochem. 162, 156-159 (1987)). A calibration curve for miR-21 Northern signals was produced by loading increasing amounts (10 to 30000 pg) of synthetically made miR-21 (Lim et al. et al., Genes & Devel. 17, 991-1008 (2003)). Northern blot analysis was performed as described using 30 μ g of total RNA per well (Lagos-Quintana et al., Science 294, 853-858 (2001)).

In vitro miRNA cleavage and inhibition assay

2'-O-Methyl oligoribonucleotides or 2'-deoxyoligonucleotides were pre-incubated with HeLa S100 at 30 °C for 20 min prior to the addition of the cap-labeled miR-21 target RNA. The concentration of the reaction components were 5 nM target RNA, 1 mM ATP, 0.2 mM GTP, 10 U/ml RNasin (Promega) and 50% HeLa S100 extract in a final reaction volume of 25 μ l. The reaction time was 1.5 h at 30 °C. The reaction was stopped by addition of 200 μ l of 300 mM NaCl/25 mM EDTA/20% w/v SDS/200 mM Tris HCl (pH 7.5). Subsequently, proteinase K was added to a final concentration of 0.6 mg/ml and the sample was incubated for 15 min at 65 °C. After phenol/chloroform extraction, the RNA was ethanol-precipitated and separated on a 6% denaturing polyacrylamide gel. Radioactivity was detected by phosphorimaging.

Cell culture and transfection

HeLa S3 and HeLa S3/GFP were grown in 5% CO₂ at 37 °C in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 unit/ml penicillin, and 100 µg/ml streptomycin. One day before transfection, 105 cells were plated in 500 µl DMEM containing 10% FBS per well of a 24-well plate. Plasmid and plasmid/oligonucleotide transfection was carried out with Lipofectamine2000 (Invitrogen). 0.2 µg pEGFP or its derivatives were cotransfected with 0.3 µg pHcRed with or without 10 pmol of 2'-O-methyl oligoribonucleotide or 10 pmol of 2'-deoxyoligonucleotide per well. Fluorescent cell images were recorded on a Zeiss Axiovert 200 inverted fluorescence microscope (Plan-Apochromat 10x/0.45) equipped with Chroma Technology Corp. filter sets 41001 (EGFP) and 41002c (HcRed) and AxioVision 3.1 software.

Example 2: MicroRNA-21 Cleavage of Target RNA

In order to assess the ability of modified oligonucleotides to specifically interfere with miRNA function, we used our previously described mammalian biochemical system developed for assaying RISC activity (Martinez et al., *Cell* 100, 563-574 (2002)). Zamore and colleagues (Hutvagner et al., *Science* 297, 2056-2050 (2002)) showed that crude cytoplasmic cell lysates and eIF2C2 immunoprecipitates prepared from these lysates contain let-7 RNPs that specifically cleave let-7-complementary target RNAs. We previously reported that in HeLa cells, numerous miRNAs are expressed including several let-7 miRNA variants (Lagos-Quintana et al., *Science* 294, 853-858 (2001)).

To assess if other HeLa cell miRNAs are also engaged in RISC like miRNPs we examined the cleavage of a 32P-cap-labelled substrate RNA with a complementary site to the highly expressed miR-21 (Lagos-Quintana et al., *Science* 294, 853-858 (2001); Mourelatos et al., *Genes & Dev.* 16, 720-728 (2002)). Sequence-specific target RNA degradation was readily observed and appeared to be approximately 2- to 5-fold more effective than cleavage of a similar let-7 target RNA (Figure 2A, lane 1, and data not shown). We therefore decided to interfere with miR-21 guided target RNA cleavage.

Example 3: Anti MicroRNA-21 2'-O-methyl Oligoribonucleotide Inhibited MicroRNA-21-Induced Cleavage of Target RNA

A 24-nucleotide 2'-O-methyl oligoribonucleotide that contained a 3' C7 aminolinker and was complementary to the longest form of the miR-21 was synthesized. The aminolinker was introduced in order to enable post-synthetic conjugation of non-nucleotidic residues such as biotin.

Increasing concentrations of anti miR-21 2'-O-methyl oligoribonucleotide and a control 2'-O-methyl oligoribonucleotide cognate to an EGFP sequence were added to the S100 extract 20 min prior to the addition of ³²P-cap-labelled substrate. We determined the concentration of miR-21 in the S100 extract by quantitative Northern blotting to be 50 pM (Lim et al., *Genes & Devel.* 17, 991-1008 (2003)).

The control EGFP oligonucleotide did not interfere with miR-21 cleavage even at the highest applied concentration (Figure 2A, lanes 2-3). In contrast, the activity of miR-21 was completely blocked at a concentration of only 3 nM (Figure 2A, lane 5), and a concentration of 0.3 nM showed a substantial 60%-70% reduction of cleavage activity (Figure 2, lane 6). At a concentration of 0.03 nM, the cleavage activity of miR-21 was not affected when compared to the lysate alone (Figure 2, lane 1, 7).

Antisense 2'-deoxyoligonucleotides (approximately 90% DNA molecules) at concentrations identical to those of 2'-O-methyl oligoribonucleotides, we could not detect blockage of miR-21 induced cleavage (Figure 2A, lanes 8-10). The 2'-deoxynucleotides used in this study were protected against 3'-exonucleases by the addition of three 2'-O-methyl ribonucleotide residues.

Example 4: Anti MicroRNA-21 2'-O-methyl Oligoribonucleotide Inhibited MicroRNA-21-Induced Cleavage of Target RNA *In Vitro*

In order to monitor the activity of miR-21 in HeLa cells, we constructed reporter plasmids that express EGFP mRNA that contains in its 3' UTR a 22-nt sequence complementary to miR-21 (pEGFP-S-21) or in sense orientation to miR-21 (p-EGFP-A-21). Endogenous miRNAs have previously been shown to act like siRNAs by cleaving reporter mRNAs carrying

sequences perfectly complementary to miRNA. To monitor transfection efficiency and specific interference with the EGFP indicator plasmids, the far-red fluorescent protein encoding plasmid pHcRed-C1 was cotransfected.

Expression of EGFP was observed in HeLa cells transfected with pEGFP and pEGFP-A-21 (Figure 3, rows 1 and 2), but not from those transfected with pEGFP-S-21 (Figure 3, row 3). However, expression of EGFP from pEGFP-S-21 was restored upon cotransfection with anti miR-21 2'-O-methyl oligoribonucleotide (Figure 3, row 4). Consistent with our above observation, the 2'-deoxy anti miR-21 oligonucleotide showed no effect (Figure 3, row 5).

Similarly, cotransfection of the EGFP 2'-O-methyl oligoribonucleotide in sense orientation with respect to the EGFP mRNA (or antisense to EGFP guide siRNA) had no effect (Figure 3, row 6).

We have demonstrated that miRNP complexes can be effectively and sequence-specifically inhibited with 2'-O-methyl oligoribonucleotides antisense to the guide strand positioned in the RNA silencing complex.

What we claim is:

1. An isolated single stranded anti-microRNA molecule comprising a minimum of ten moieties and a maximum of fifty moieties on a molecular backbone, the molecular backbone comprising backbone units, each moiety comprising a base bonded to a backbone unit, each base forming a Watson-Crick base pair with a complementary base wherein:

at least ten contiguous bases have the same sequence as a sequence of bases in any one of the anti-microRNA molecules shown in Tables 1-4, except that up to thirty percent of the bases pairs may be wobble base pairs, and up to 10% of the contiguous bases may be additions, deletions, mismatches, or combinations thereof;

no more than fifty percent of the contiguous moieties contain deoxyribonucleotide backbone units;

the moiety in the molecule at the position corresponding to position 11 of the microRNA is non-complementary; and

the molecule is capable of inhibiting microRNP activity.

2. A molecule according to claim 1, wherein up to 5% of the contiguous moieties are additions, deletions, mismatches, or combinations thereof.

3. A molecule according to claim 1, wherein at least one of the moieties is a deoxyribonucleotide.

4. A molecule according to claim 3, wherein the deoxyribonucleotide is a modified deoxyribonucleotide moiety.

5. A molecule according to claim 4, wherein the modified deoxyribonucleotide is a phosphorothioate deoxyribonucleotide moiety.

6. A molecule according to claim 4, wherein the modified deoxyribonucleotide is N³-N⁵ phosphoroamidate deoxyribonucleotide moiety.

7. A molecule according to claim 1, wherein at least one of the moieties is a ribonucleotide moiety.
8. A molecule according to claim 7, wherein at least one of the moieties is a modified ribonucleotide moiety.
9. A molecule according to claim 8, wherein the modified ribonucleotide is substituted at the 2' position.
10. A molecule according to claim 9, wherein the substituent at the 2' position is a C₁ to C₄ alkyl group.
11. A molecule according to claim 10, wherein the alkyl group is methyl.
12. A molecule according to claim 10, wherein the alkyl group is allyl.
13. A molecule according to claim 9, wherein the substituent at the 2' position is a C₁ to C₄ alkoxy - C₁ to C₄ alkyl group.
14. A molecule according to claim 13, wherein the C₁ to C₄ alkoxy - C₁ to C₄ alkyl group is methoxyethyl.
15. A molecule according to claim 8, wherein the modified ribonucleotide has a methylene bridge between the 2'-oxygen atom and the 4'-carbon atom.
16. A molecule according to claim 1, wherein at least one of the moieties is a peptide nucleic acid moiety.
17. A molecule according to claim 1, wherein at least one of the moieties is a 2'-fluororibonucleotide moiety.
18. A molecule according to claim 1, wherein at least one of the moieties is a morpholino phosphoroamidate nucleotide moiety.
19. A molecule according to claim 1, wherein at least one of the moieties is a tricyclo nucleotide moiety.

20. A molecule according to claim 1, wherein at least one of the moieties is a cyclohexene nucleotide moiety.
21. A molecule according to claim 1, wherein the molecule comprises at least one modified moiety for increased nuclease resistance.
22. A molecule according to claim 21, wherein the nuclease is an exonuclease.
23. A molecule according to claim 22, wherein the molecule comprises at least one modified moiety at the 5' end.
24. A molecule according to claim 22, wherein the molecule comprises at least two modified moieties at the 5' end.
25. A molecule according to claim 22, wherein the molecule comprises at least one modified moiety at the 3' end.
26. A molecule according to claim 22, wherein the molecule comprises at least two modified moieties at the 3' end.
27. A molecule according to claim 22, wherein the molecule comprises at least one modified moiety at the 5' end and at least one modified moiety at the 3' end.
28. A molecule according to claim 22, wherein the molecule comprises at least two modified moieties at the 5' end and at least two modified moieties at the 3' end.
29. A molecule according to claim 22, wherein the molecule comprises a nucleotide cap at the 5' end, the 3' end or both.
30. A molecule according to claim 22, wherein the molecule comprises an ethylene glycol compound and/or amino linkers at the 5' end, the 3' end, or both.
31. A molecule according to claim 1, wherein the nuclease is an endonuclease.
32. A molecule according to claim 31, wherein the molecule comprises at least one modified moiety between the 5' and 3' end.

33. A molecule according to claim 31, wherein the molecule comprises an ethylene glycol compound and/or amino linker between the 5' end and 3' end.

34. A molecule according to claim 1, wherein all of the moieties are nuclease resistant.

35. A method for inhibiting microRNP activity in a cell, the microRNP comprising a microRNA molecule, the microRNA molecule comprising a sequence of bases complementary of the sequence of bases in a single stranded anti-microRNA molecule, the method comprising introducing into the cell the single-stranded anti-microRNA molecule comprising a sequence of a minimum of ten moieties and a maximum of fifty moieties on a molecular backbone, the molecular backbone comprising backbone units, each moiety comprising a base bonded to a backbone unit, each base forming a Watson-Crick base pair with a complementary base, wherein:

at least ten contiguous bases of the anti-microRNA molecule are complementary to the microRNA, except that up to thirty percent of the bases may be substituted by wobble base pairs, and up to ten percent of the at least ten moieties are addition, deletions, mismatches, or combinations thereof;

no more than fifty percent of the contiguous moieties contain deoxyribonucleotide backbone units; and

the moiety in the molecule at the position corresponding to position 11 of the microRNA is non-complementary.

36. A method according to claim 35, wherein the anti-microRNA is a human anti-microRNA.

37. A method according to claim 35, wherein the anti-microRNA is a mouse anti-microRNA.

38. A method according to claim 35, wherein the anti-microRNA is a rat anti-microRNA.

39. A method according to claim 35, wherein the anti-microRNA is a drosophila microRNA.

40. A method according to claim 35, wherein the anti-microRNA is a C. elegans microRNA.

41. An isolated microRNA molecule comprising a minimum of ten moieties and a maximum of fifty moieties on a molecular backbone, the molecular backbone comprising backbone units, each moiety comprising a base bonded to a backbone unit wherein:

at least ten contiguous bases have the same sequence as a sequence of bases in any one of the microRNA molecules shown in Table 2, except that up to thirty percent of the bases pairs may be wobble base pairs, and up to 10% of the contiguous bases are additions, deletions, mismatches, or combinations thereof; and

no more than fifty percent of the contiguous moieties contain deoxyribonucleotide backbone units.

42. A molecule according to claim 41 having the sequence shown in Table 2.

43. A molecule according to claim 41, wherein the molecule is modified for increased nuclease resistance.

44. A molecule according to claim 41, wherein the moiety at position 11 is an addition, deletion or substitution.

45. An isolated microRNA molecule comprising a minimum of ten moieties and a maximum of fifty moieties on a molecular backbone, the molecular backbone comprising backbone units, each moiety comprising a base bonded to a backbone unit wherein:

at least ten contiguous bases have any one of the microRNA sequences shown in Tables 1, 3 and 4, except that up to thirty percent of the bases pairs may be wobble base pairs, and up to 10% of the contiguous bases are additions, deletions, mismatches, or combinations thereof;

no more than fifty percent of the contiguous moieties contain deoxyribonucleotide backbone units; and

is modified for increased nuclease resistance.

46. A molecule according to claim 45, wherein the molecule is modified for increased nuclease resistance.

47. A molecule according to claim 45, wherein the moiety at position 11 is an addition, deletion, or substitution.

48. An isolated single stranded anti-microRNA molecule comprising a minimum of ten moieties and a maximum of fifty moieties on a molecular backbone, the molecular backbone comprising backbone units, each moiety comprising a base bonded to a backbone unit, each base forming a Watson-Crick base pair with a complementary base wherein:

at least ten contiguous bases have the same sequence as a sequence of bases in any one of the anti-microRNA molecules shown in Tables 1-4, except that up to thirty percent of the bases pairs may be wobble base pairs, and up to 10% of the contiguous bases may be additions, deletions, mismatches, or combinations thereof;


no more than fifty percent of the contiguous moieties contain deoxyribonucleotide backbone units; and

the molecule is capable of inhibiting microRNP activity.


49. A method for inhibiting microRNP activity in a cell, the microRNP comprising a microRNA molecule, the microRNA molecule comprising a sequences of bases complementary of the sequence of bases in a single stranded anti-microRNA molecule, the method comprising introducing into the cell the single-stranded anti-microRNA molecule comprising a sequence of a minimum of ten moieties and a maximum of fifty moieties on a molecular backbone, the molecular backbone comprising backbone units, each moiety comprising a base bonded to a backbone unit, each base forming a Watson-Crick base pair with a complementary base, wherein:

at least ten contiguous bases of the anti-microRNA molecule are complementary to the microRNA, except that up to thirty percent of the bases may be substituted by wobble base pairs, and up to ten percent of the at least ten moieties may be additions, deletions, mismatches, or combinations thereof; and


no more than fifty percent of the contiguous moieties contain deoxyribonucleotide backbone units.

Figure 1


Phosphorothioate DNA Unit
(PS)
Structure 1




2'-O-methyl RNA unit
(OMe)
Structure 3




2'-O-methoxy-ethyl RNA unit
(MOE)
Structure 4




Peptide nucleic acid unit
(PNA)
Structure 6




N3'-P5' Phosphoroamidate DNA unit
(NP)
Structure 2




2'-fluoro-ribo nucleic acid unit
(FANA)
Structure 7




Locked nucleic acid unit
(LNA)
Structure 5



Morpholino phosphoroamidate
nucleic acid unit
(MF)
Structure 8



Cyclohexane nucleic acid unit
(CeNA)
Structure 10



Tricyclonucleic acid unit
Structure 9

Figure 2





Figure 3



1119-10CON-PCT.ST25
SEQUENCE LISTING

<110> The Rockefeller University

<120> Anti-MicroRNA Oligonucleotide Molecules

<130> 1119-10 CON/PCT

<140> unknown

<141> 2005-02-11

<150> US 10/845,057

<151> 2004-05-13

<150> US 10/778,908

<151> 2004-02-13

<160> 623

<170> PatentIn version 3.1

<210> 1

<211> 22

<212> RNA

<213> Homo sapiens

<400> 1
aaccgguaga uccgaacuug ug 22

<210> 2

<211> 22

<212> RNA

<213> Homo sapiens

<400> 2
agcagcauug uacagggcuà ug 22

<210> 3

<211> 22

<212> RNA

<213> Homo sapiens

<400> 3
ucaaaugcuc agacuccugu gg 22

<210> 4

<211> 22

<212> RNA

<213> Homo sapiens

<400> 4
aaaagugcuu acagugcagg ua 22

<210> 5

<211> 22

<212> RNA

<213> Homo sapiens

<400> 5
uaaagugcug acagugcaga ua 22

1119-10CON-PCT.ST25

<210> 6
<211> 22
<212> RNA
<213> Homo sapiens

<400> 6
agcagcauug uacagggcua uc 22

<210> 7
<211> 22
<212> RNA
<213> Homo sapiens

<400> 7
uaccuguag aaccgaauuu gu 22

<210> 8
<211> 22
<212> RNA
<213> Homo sapiens

<400> 8
ucacagugaa ccggucucu uc 22

<210> 9
<211> 22
<212> RNA
<213> Homo sapiens

<400> 9
cagugcaaug augaaagggc au 22

<210> 10
<211> 22
<212> RNA
<213> Homo sapiens

<400> 10
uaccacaggg uagaaccacg ga 22

<210> 11
<211> 22
<212> RNA
<213> Homo sapiens

<400> 11
cccauaaagu agaaagcacu ac 22

<210> 12
<211> 22
<212> RNA
<213> Homo sapiens

<400> 12
ucgaggagcu cacagucuag ua 22

1119-10CON-PCT.ST25

<210> 13
<211> 22
<212> RNA
<213> Homo sapiens

<400> 13
uuaaugcuaa ucgugauagg gg 22

<210> 14
<211> 22
<212> RNA
<213> Homo sapiens

<400> 14
aacauucaac gcugucggug ag 22

<210> 15
<211> 22
<212> RNA
<213> Homo sapiens

<400> 15
aacauucauu gcugucggug gg 22

<210> 16
<211> 22
<212> RNA
<213> Homo sapiens

<400> 16
aacauucaac cugucgguga gu 22

<210> 17
<211> 22
<212> RNA
<213> Homo sapiens

<400> 17
uuuggcaaug guagaacuca ca 22

<210> 18
<211> 22
<212> RNA
<213> Homo sapiens

<400> 18
uauggcacug guagaauuca cu 22

<210> 19
<211> 22
<212> RNA
<213> Homo sapiens

<400> 19
uggacggaga acugauaagg gu 22

1119-10CON-PCT.ST25

<210> 20
<211> 22
<212> RNA
<213> Homo sapiens

<400> 20
uggagagaaa ggcaguuccu ga

22

<210> 21
<211> 22
<212> RNA
<213> Homo sapiens

<400> 21
caaagaauuc uccuuuuggg cu

22

<210> 22
<211> 22
<212> RNA
<213> Homo sapiens

<400> 22
ucgugucuug uguugcagcc gg

22

<210> 23
<211> 22
<212> RNA
<213> Homo sapiens

<400> 23
cucccacaug caggguuugc ag

22

<210> 24
<211> 22
<212> RNA
<213> Homo sapiens

<400> 24
caucccuugc augguggagg gu

22

<210> 25
<211> 22
<212> RNA
<213> Homo sapiens

<400> 25
gugccuacug agcugauauc ag

22

<210> 26
<211> 22
<212> RNA
<213> Homo sapiens

<400> 26
ugauauguuu gauauuuag gu

22

<210> 27

1119-10CON-PCT.ST25

<211> 22
<212> RNA
<213> Homo sapiens

<400> 27
caacggauc ccaaaagcag cu 22

<210> 28
<211> 22
<212> RNA
<213> Homo sapiens

<400> 28
cugaccuaug aaugacagc ca 22

<210> 29
<211> 22
<212> RNA
<213> Homo sapiens

<400> 29
aacuggccua caaagucca gu 22

<210> 30
<211> 22
<212> RNA
<213> Homo sapiens

<400> 30
ugggucuuug cgggcaagau ga 22

<210> 31
<211> 22
<212> RNA
<213> Homo sapiens

<400> 31
uguaacagca acuccaugug ga 22

<210> 32
<211> 22
<212> RNA
<213> Homo sapiens

<400> 32
uagcagcaca gaaauauugg ca 22

<210> 33
<211> 22
<212> RNA
<213> Homo sapiens

<400> 33
uagguaguuu cauguuguug gg 22

<210> 34
<211> 22

1119-10CON-PCT.ST25

<212> RNA
<213> Homo sapiens

<400> 34
uucaccaccu ucuccaccca gc

22

<210> 35
<211> 22
<212> RNA
<213> Homo sapiens

<400> 35
gguccagagg ggagauaggu uc

22

<210> 36
<211> 22
<212> RNA
<213> Homo sapiens

<400> 36
acaguagucu gcacauuggu ua

22

<210> 37
<211> 22
<212> RNA
<213> Homo sapiens

<400> 37
cccaguguuc agacuaccug uu

22

<210> 38
<211> 22
<212> RNA
<213> Homo sapiens

<400> 38
cccaguguuu agacuaucug uu

22

<210> 39
<211> 22
<212> RNA
<213> Homo sapiens

<400> 39
uaacacuguc ugguaacgau gu

22

<210> 40
<211> 22
<212> RNA
<213> Homo sapiens

<400> 40
cucuaauacu gccugguaau ga

22

<210> 41
<211> 22
<212> RNA

1119-10CON-PCT.ST25

<213> Homo sapiens

<400> 41

aauacugccg gguaaugaug ga

22

<210> 42

<211> 22

<212> RNA

<213> Homo sapiens

<400> 42

gugaaauguu uaggaccacu ag

22

<210> 43

<211> 22

<212> RNA

<213> Homo sapiens

<400> 43

uucccuuugu cauccaugc cu

22

<210> 44

<211> 22

<212> RNA

<213> Homo sapiens

<400> 44

uccuucauuc caccggaguc ug

22

<210> 45

<211> 22

<212> RNA

<213> Homo sapiens

<400> 45

uggaauguaa ggaagugugu gg

22

<210> 46

<211> 22

<212> RNA

<213> Homo sapiens

<400> 46

auaagacgag caaaaagcuu gu

22

<210> 47

<211> 22

<212> RNA

<213> Homo sapiens

<400> 47

cugugcgugu gacagcggu ga

22

<210> 48

<211> 22

<212> RNA

<213> Homo sapiens

1119-10CON-PCT.ST25

<400> 48
uucccuuugu cauccuucgc cu 22

<210> 49
<211> 22
<212> RNA
<213> Homo sapiens

<400> 49
uaacagucuc cagucacggc ca 22

<210> 50
<211> 22
<212> RNA
<213> Homo sapiens

<400> 50
accaucgacc guugauugua cc 22

<210> 51
<211> 22
<212> RNA
<213> Homo sapiens

<400> 51
acagcaggca cagacaggca gu 22

<210> 52
<211> 22
<212> RNA
<213> Homo sapiens

<400> 52
augaccuaug aauugacaga ca 22

<210> 53
<211> 22
<212> RNA
<213> Homo sapiens

<400> 53
uaaucucagc uggcaacugu ga 22

<210> 54
<211> 22
<212> RNA
<213> Homo sapiens

<400> 54
uacugcauca ggaacugauu gg 22

<210> 55
<211> 22
<212> RNA
<213> Homo sapiens

1119-10CON-PCT.ST25

<400> 55
UUGUGCUUGA UCUAACCAUG UG 22

<210> 56
<211> 22
<212> RNA
<213> Homo sapiens

<400> 56
UGAUUGUCCA AACGCAAUUC UU 22

<210> 57
<211> 22
<212> RNA
<213> Homo sapiens

<400> 57
CCACACCGUA UCUGACACUU UG 22

<210> 58
<211> 22
<212> RNA
<213> Homo sapiens

<400> 58
AGCUACAUG UCUGCUGGGU UU 22

<210> 59
<211> 22
<212> RNA
<213> Homo sapiens

<400> 59
AGCUACAUCU GGCUACUGGG UC 22

<210> 60
<211> 22
<212> RNA
<213> Homo sapiens

<400> 60
UGUCAGUUUG UCAAUACCC CA 22

<210> 61
<211> 22
<212> RNA
<213> Homo sapiens

<400> 61
CAAGUCACUA GUGGUUCCGU UU 22

<210> 62
<211> 22
<212> RNA
<213> Homo sapiens

<400> 62

1119-10CON-PCT.ST25

aaggagcuca cagucuauug ag

22

<210> 63
<211> 22
<212> RNA
<213> Homo sapiens

<400> 63
cucaaacugu gggggcacuu uc

22

<210> 64
<211> 22
<212> RNA
<213> Homo sapiens

<400> 64
agggccccc cucaauccug uu

22

<210> 65
<211> 22
<212> RNA
<213> Homo sapiens

<400> 65
ugguuuaccg ucccacauac au

22

<210> 66
<211> 22
<212> RNA
<213> Homo sapiens

<400> 66
cagugcaaua guauugucua ag

22

<210> 67
<211> 22
<212> RNA
<213> Homo sapiens

<400> 67
uaagugcuuc cauguuuugg ug

22

<210> 68
<211> 22
<212> RNA
<213> Homo sapiens

<400> 68
uguaaacau cuugacugga ag

22

<210> 69
<211> 22
<212> RNA
<213> Homo sapiens

<400> 69
aaaagcuggg uugagagggc ga

22

1119-10CON-PCT.ST25

<210> 70
<211> 22
<212> RNA
<213> Homo sapiens

<400> 70
uaagccaggg auuguggguu cg

22

<210> 71
<211> 22
<212> RNA
<213> Homo sapiens

<400> 71
aaacaugaau ugcugcugua uc

22

<210> 72
<211> 22
<212> RNA
<213> Homo sapiens

<400> 72
gcacauuaca cggucgaccu cu

22

<210> 73
<211> 22
<212> RNA
<213> Homo sapiens

<400> 73
ccacugcccc aggugcugcu gg

22

<210> 74
<211> 22
<212> RNA
<213> Homo sapiens

<400> 74
cgcauccccu agggcauugg ug

22

<210> 75
<211> 22
<212> RNA
<213> Homo sapiens

<400> 75
ccucugggcc cuuccuccag cc

22

<210> 76
<211> 22
<212> RNA
<213> Homo sapiens

<400> 76
cuggcccucu cugcccuucc gu

22

1119-10CON-PCT.ST25

<210> 77
<211> 22
<212> RNA
<213> Homo sapiens

<400> 77
aacacaccca gcuaaccuuu uu

22

<210> 78
<211> 22
<212> RNA
<213> Homo sapiens

<400> 78
uggcaguguc uuagcugguu gu

22

<210> 79
<211> 22
<212> RNA
<213> Homo sapiens

<400> 79
aggcaguguc auuagcugau ug

22

<210> 80
<211> 22
<212> RNA
<213> Homo sapiens

<400> 80
aggcagugua guuagcugau ug

22

<210> 81
<211> 22
<212> RNA
<213> Homo sapiens

<400> 81
uauugcacuu gucccggccu gu

22

<210> 82
<211> 22
<212> RNA
<213> Homo sapiens

<400> 82
aaagugcugu ucgugcaggu ag

22

<210> 83
<211> 22
<212> RNA
<213> Homo sapiens

<400> 83
uucaacgggu auuuauugag ca

22

1119-10CON-PCT.ST25

<210> 84
<211> 22
<212> RNA
<213> Homo sapiens

<400> 84
uuuggcacua gcacauuuuu gc

22

<210> 85
<211> 22
<212> RNA
<213> Homo sapiens

<400> 85
ugagguagua aguuguauug uu

22

<210> 86
<211> 22
<212> RNA
<213> Mouse

<400> 86
caaagugcua acagugcagg ua

22

<210> 87
<211> 22
<212> RNA
<213> Mouse

<400> 87
cccuguagaa ccgaauuugu gu

22

<210> 88
<211> 22
<212> RNA
<213> Mouse

<400> 88
uauggcuuuu cauuccuaug ug

22

<210> 89
<211> 22
<212> RNA
<213> Mouse

<400> 89
ucagugcauc acagaacuuu gu

22

<210> 90
<211> 22
<212> RNA
<213> Mouse

<400> 90
cuagacugag gcuccuugag ga

22

<210> 91

1119-10CON-PCT.ST25

<211> 22
<212> RNA
<213> Mouse

<400> 91
uuaaugcuaa uugugauagg gg

22

<210> 92
<211> 22
<212> RNA
<213> Mouse

<400> 92
cccaguguuu agacuaccug uu

22

<210> 93
<211> 22
<212> RNA
<213> Mouse

<400> 93
uaauacugcc ugguaaugau ga

22

<210> 94
<211> 22
<212> RNA
<213> Mouse

<400> 94
ugaaauguuu aggaccacua ga

22

<210> 95
<211> 22
<212> RNA
<213> Mouse

<400> 95
uucccuuugu cauccuuugc cu

22

<210> 96
<211> 22
<212> RNA
<213> Mouse

<400> 96
uacugcauca ggaacugacu gg

22

<210> 97
<211> 22
<212> RNA
<213> Mouse

<400> 97
uaagucacua gugguuccgu uu

22

<210> 98
<211> 22

1119-10CON-PCT.ST25

<212> RNA
<213> Mouse

<400> 98
cacuagauug ugagcugcug ga

22

<210> 99
<211> 22
<212> RNA
<213> Mouse

<400> 99
cucaaacuau gggggcacuu uu

22

<210> 100
<211> 22
<212> RNA
<213> Mouse

<400> 100
aaagugcuuc cacuuugugu gc

22

<210> 101
<211> 22
<212> RNA
<213> Mouse

<400> 101
caucaaagug gaggcccucu cu

22

<210> 102
<211> 22
<212> RNA
<213> Mouse

<400> 102
aagugccgcc agguuuugag ug

22

<210> 103
<211> 22
<212> RNA
<213> Mouse

<400> 103
acucaaacug ggggcucuuu ug

22

<210> 104
<211> 22
<212> RNA
<213> Mouse

<400> 104
agugccgcag aguuuguagu gu

22

<210> 105
<211> 22
<212> RNA

1119-10CON-PCT.ST25

<213> Mouse

<400> 105

aaagugcuuc ccuuuugugu gu

22

<210> 106

<211> 22

<212> RNA

<213> Mouse

<400> 106

aaagugcuac uacuuuugag uc

22

<210> 107

<211> 22

<212> RNA

<213> Mouse

<400> 107

auguaugugu gcaugugcau gu

22

<210> 108

<211> 22

<212> RNA

<213> Mouse

<400> 108

ggcagaggag ggcuguucuu cc

22

<210> 109

<211> 22

<212> RNA

<213> Mouse

<400> 109

uaugcaaggg caagcucucu uc

22

<210> 110

<211> 22

<212> RNA

<213> Mouse

<400> 110

aggcaagaug cuggcauagc ug

22

<210> 111

<211> 22

<212> RNA

<213> Mouse

<400> 111

aaacaugaag cgcugcaaca cc

22

<210> 112

<211> 22

<212> RNA

<213> Mouse

1119-10CON-PCT.ST25

<400> 112
ccuaguaggu gcucaguaag ug

22

<210> 113
<211> 22
<212> RNA
<213> Mouse

<400> 113
ccucugggcc cuuccuccag uc

22

<210> 114
<211> 22
<212> RNA
<213> Mouse

<400> 114
gcaaagcaca gggccugcag ag

22

<210> 115
<211> 22
<212> RNA
<213> Mouse

<400> 115
gccccugggc cuauccuaga ac

22

<210> 116
<211> 22
<212> RNA
<213> Mouse

<400> 116
uucaguccu auaugaugcc uu

22

<210> 117
<211> 22
<212> RNA
<213> Mouse

<400> 117
uccagcauca gugauuuugu ug

22

<210> 118
<211> 22
<212> RNA
<213> Mouse

<400> 118
ucccuguccu ccaggagcuc ac

22

<210> 119
<211> 22
<212> RNA
<213> Mouse

1119-10CON-PCT.ST25

<400> 119
uccgucucag uuacuuuaua gc

22

<210> 120
<211> 22
<212> RNA
<213> Mouse

<400> 120
ucgaucgguc ggucggucag uc

22

<210> 121
<211> 22
<212> RNA
<213> Mouse

<400> 121
ucucacacag aaaucgcacc cg

22

<210> 122
<211> 22
<212> RNA
<213> Mouse

<400> 122
ugaucuagcc aaagccugac ug

22

<210> 123
<211> 22
<212> RNA
<213> Mouse

<400> 123
ugcugacccc uaguccagug cu

22

<210> 124
<211> 22
<212> RNA
<213> Mouse

<400> 124
ugucugcccg agugccugcc uc

22

<210> 125
<211> 22
<212> RNA
<213> Mouse

<400> 125
uaggcagugu aaauagcuga uu

22

<210> 126
<211> 22
<212> RNA
<213> Mouse

<400> 126

1119-10CON-PCT.ST25

uucacaaagc cc <u>au</u> acacuu uc	22
<210> 127	
<211> 22	
<212> RNA	
<213> Mouse	
<400> 127	
ucccugagga gccc <u>uu</u> ugag cc	22
<210> 128	
<211> 22	
<212> RNA	
<213> Mouse	
<400> 128	
uggaagacuu gug <u>auuuu</u> gu ug	22
<210> 129	
<211> 22	
<212> RNA	
<213> Mouse	
<400> 129	
uauugcacuu gucccggccu ga	22
<210> 130	
<211> 22	
<212> RNA	
<213> Mouse	
<400> 130	
caaagugcug uucgugcagg ua	22
<210> 131	
<211> 22	
<212> RNA	
<213> Rat	
<400> 131	
ccuugagggg caugágggua gu	22
<210> 132	
<211> 22	
<212> RNA	
<213> Rat	
<400> 132	
guggugugcu agu <u>uacuuuu</u> gg	22
<210> 133	
<211> 22	
<212> RNA	
<213> Rat	
<400> 133	
ucaagagcaa uaacgaaaaa ug	22

1119-10CON-PCT.ST25

<210> 134
<211> 22
<212> RNA
<213> Rat

<400> 134
ucacccuucc auaucuaguc uc

22

<210> 135
<211> 22
<212> RNA
<213> Rat

<400> 135
ucucccuccg ugugcccagu au

22

<210> 136
<211> 22
<212> RNA
<213> Rat

<400> 136
ugucccucug ggucgcccag cu

22

<210> 137
<211> 22
<212> RNA
<213> Rat

<400> 137
cagcccugcu gucuuaaccu cu

22

<210> 138
<211> 22
<212> RNA
<213> Rat

<400> 138
agaguaguag guugcauagu ac

22

<210> 139
<211> 22
<212> RNA
<213> Homo sapiens

<400> 139
uuaucagaau cuccaggggu ac

22

<210> 140
<211> 22
<212> RNA
<213> Homo sapiens

<400> 140
aauccuugga accuaggugu ga

22

1119-1OCON-PCT.ST25

<210> 141
<211> 22
<212> RNA
<213> Homo sapiens

<400> 141
auugcacggu auccaucugu aa 22

<210> 142
<211> 22
<212> RNA
<213> Homo sapiens

<400> 142
cggcggggac ggcgauuggu cc 22

<210> 143
<211> 22
<212> RNA
<213> Homo sapiens

<400> 143
uaaugcccu aaaaauccuu au 22

<210> 144
<211> 22
<212> RNA
<213> Homo sapiens

<400> 144
uaacugguug aacaacugaa cc 22

<210> 145
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 145
ugagguagua gguuguauag uu 22

<210> 146
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 146
ucccugagac cucaagugug ag 22

<210> 147
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 147
uggaanguaa agaaguaugu ag 22

1119-10CON-PCT.ST25

<210> 148
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 148
uaucaacagcc agcuuugaug ug 22

<210> 149
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 149
aggcagugug guuagcuggu ug 22

<210> 150
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 150
ucaccgggug gaaacuagca gu 22

<210> 151
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 151
ucaccgggug aaaauucgca ug 22

<210> 152
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 152
ucaccgggug aacacuugca gu 22

<210> 153
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 153
ucaccgggag aaaaacugga gu 22

<210> 154
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 154
ucaccgggug uaaaucagcu ug 22

<210> 155

1119-10CON-PCT.ST25

<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 155
ucaccgggug uacaucagcu aa 22

<210> 156
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 156
ucaccgggug aaaaaucacc ua 22

<210> 157
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 157
caccggguua acaucuacag ag 22

<210> 158
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 158
uauacaguu uacuugcugu cg 22

<210> 159
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 159
ugacuagaga cacauucagc uu 22

<210> 160
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 160
ugacuagaga cacauucagc uu 22

<210> 161
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 161
ugucauggag ucgcucucuu ca 22

<210> 162
<211> 22

1119-10CON-PCT.ST25

<212> RNA
<213> Caenorhabditis elegans

<400> 162
ugucauggag gcgcucucuu ca 22

<210> 163
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 163
ugagguaggc ucaguagaug cg 22

<210> 164
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 164
aagcaccacg agaagcugca ga 22

<210> 165
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 165
ugauaugucu gguauucuug gg 22

<210> 166
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 166
uacccguagc uccuauccau gu 22

<210> 167
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 167
cacccguaca uauguuuccg ug 22

<210> 168
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 168
cacccguaca uuuguuuccg ug 22

<210> 169
<211> 22
<212> RNA

1119-10CON-PCT.ST25

<213> Caenorhabditis elegans
<400> 169
uacccguaau cuucauaauc cg 22

<210> 170
<211> 22
<212> RNA
<213> Caenorhabditis elegans
<400> 170
uacccguaua aguuucugcu ga 22

<210> 171
<211> 22
<212> RNA
<213> Caenorhabditis elegans
<400> 171
uacccguaau guuuccgcug ag 22

<210> 172
<211> 22
<212> RNA
<213> Caenorhabditis elegans
<400> 172
uacccuguag aucgagcugu gu 22

<210> 173
<211> 22
<212> RNA
<213> Caenorhabditis elegans
<400> 173
ugagaucguu caguacggca au 22

<210> 174
<211> 22
<212> RNA
<213> Caenorhabditis elegans
<400> 174
ucgaaucguu uaucaggaug au 22

<210> 175
<211> 22
<212> RNA
<213> Caenorhabditis elegans
<400> 175
uauuaugcac auuuucuagu uc 22

<210> 176
<211> 22
<212> RNA
<213> Caenorhabditis elegans

1119-10CON-PCT.ST2 5

<400> 176
ugacuagaac cguuacucau cu 22

<210> 177
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 177
ugauauguaa ucuagcuuac ag 22

<210> 178
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 178
augacacuga agcgaguugg aa 22

<210> 179
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 179
uauagacacug aagcguuacc ga 22

<210> 180
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 180
uauagacacug aagcguaacc ga 22

<210> 181
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 181
caugacacug auuagggauug ug 22

<210> 182
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 182
ucacaaccuc cuagaaagag ua 22

<210> 183
<211> 22
<212> RNA
<213> Caenorhabditis elegans

1119-10CON-PCT.ST25

<400> 183
ucgaagacuc aaaaguguag ac 22

<210> 184
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 184
ucgaaaauua aaaaguguag aa 22

<210> 185
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 185
uaauacgucg uugguguuuc ca 22

<210> 186
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 186
ugaaagacau gguagugaa cg 22

<210> 187
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 187
aggcaaug uaggcauagc ug 22

<210> 188
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 188
uggcaaug uaggcaguuc ag 22

<210> 189
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 189
uggcaagaaa uggcagucua ca 22

<210> 190
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 190

1119-10CON-PCT.ST25

uuaaagcuac caaccggcuu ca

22

<210> 191
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 191
uucguuguug augaagccuu ga

22

<210> 192
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 192
uucaucaggc cauagcuguc ca

22

<210> 193
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 193
uggaggccug guuguuugug cu

22

<210> 194
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 194
auaaagcuag guuaccaaag cu

22

<210> 195
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 195
agcuuucgac augauucuga ac

22

<210> 196
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 196
ugagaucauu aguugaaagc cg

22

<210> 197
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 197
ugagaucauc gugaaagcua gu

22

1119-10CON-PCT.ST25

<210> 198
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 198
ugagaucauc gugaaagcca gu 22

<210> 199
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 199
uagcaccaua uaaauucagu aa 22

<210> 200
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 200
ugagguagua uguaauauug ua 22

<210> 201
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 201
uacaaaguau uugaaaaguc gu 22

<210> 202
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 202
uaagugaaug cuuugccaca gu 22

<210> 203
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 203
gugagcaaag uuucaggugu gc 22

<210> 204
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 204
ugauauguug uuugaaugcc cc 22

1119-10CON-PCT.ST25

<210> 205
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 205
uaaggcacgc ggugaaugcc ac 22

<210> 206
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 206
aauggcacug caugaauuca cg 22

<210> 207
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 207
aaugacacug guuaucuuuu cc 22

<210> 208
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 208
guauuaguug ugcgaccagg ag 22

<210> 209
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 209
uaagcucgug aucaacaggc ag 22

<210> 210
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 210
uaaaugcauc uuaacugcgg ug 22

<210> 211
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 211
uugagcaug cgcaugugcg gg 22

1119-10CON-PCT.ST25

<210> 212
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 212
uuauugcucg agaauacccu uu 22

<210> 213
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 213
uauugcacuc uccccggccu ga 22

<210> 214
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 214
uaauacuguc agguaaugac gc 22

<210> 215
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 215
ucccugagaa uucucgaaca gc 22

<210> 216
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 216
uuuguacucc gaugccauuc ag 22

<210> 217
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 217
uuuguacuac acauagguac ug 22

<210> 218
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 218
uuuguacuac acaaaaguac ug 22

<210> 219

1119-10CON-PCT.ST25

<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 219
uacuggcccc caaaucuucg cu 22

<210> 220
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 220
ugagguaggu gcgagaaug ac 22

<210> 221
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 221
uugcguaggc cuuugcuucg ag 22

<210> 222
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 222
cgguacgauc gcggcgggau au 22

<210> 223
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 223
ucuuugguug uacaaagugg ua 22

<210> 224
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 224
auuggucccc uccaaguagc uc 22

<210> 225
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 225
uuacauguuu cgguaggag cu 22

<210> 226
<211> 22

1119-10CON-PCT.ST25

<212> RNA
<213> Caenorhabditis elegans

<400> 226
ugacuagagc cuauucucuu cu 22

<210> 227
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 227
uacacgugca cggauaacgc uc 22

<210> 228
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 228
ucacaggacu uuugagcguu gc 22

<210> 229
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 229
ucacagucaa cuguuggcau gg 22

<210> 230
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 230
uuaaguagug gugccgcucu ua 22

<210> 231
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 231
uaaguaguag ugccgcaggu aa 22

<210> 232
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 232
cacaccucac uaacacugac ca 22

<210> 233
<211> 22
<212> RNA

1119-10CON-PCT.ST25

<213> Caenorhabditis elegans

<400> 233

ugcaaaucuu ucgcgacugu ag

22

<210> 234

<211> 22

<212> RNA

<213> Caenorhabditis elegans

<400> 234

uggaaugcau agaagacugu ac

22

<210> 235

<211> 22

<212> RNA

<213> Caenorhabditis elegans

<400> 235

gaguaucagg aguacccagu ga

22

<210> 236

<211> 22

<212> RNA

<213> Caenorhabditis elegans

<400> 236

gguuuugaga ggaauccuuu ua

22

<210> 237

<211> 22

<212> RNA

<213> Caenorhabditis elegans

<400> 237

aguaaaucuc auccuaaucu gg

22

<210> 238

<211> 22

<212> RNA

<213> Caenorhabditis elegans

<400> 238

gugaugucga acucuuguag ga

22

<210> 239

<211> 22

<212> RNA

<213> Caenorhabditis elegans

<400> 239

uagcuuuuuu guuuucacgg ug

22

<210> 240

<211> 22

<212> RNA

<213> Caenorhabditis elegans

1119-10CON-PCT.ST25

<400> 240
guuucucgau guuucugau ac 22

<210> 241
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 241
ggcggguggu uguuguuau gg 22

<210> 242
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 242
ugagggagga agggugguau uu 22

<210> 243
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 243
aggcaagacu uuggcaaagc uu 22

<210> 244
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 244
cccgugaagu gucugcugca au 22

<210> 245
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 245
ggcaagaauu agaagcaguu ug 22

<210> 246
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 246
ggcaagacuc uggcaaaacu ug 22

<210> 247
<211> 22
<212> RNA
<213> Caenorhabditis elegans

1119-10CON-PCT.ST25

<400> 247
ggcaugaugu agcaguggag au 22

<210> 248
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 248
ucgccgggug ggaaagcauu cg 22

<210> 249
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 249
uguaggcaug gguguuugga ag 22

<210> 250
<211> 22
<212> RNA
<213> Caenorhabditis elegans

<400> 250
ugcccguacu gugucggcug cu 22

<210> 251
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 251
guuaauggca cuggaagaau uc 22

<210> 252
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 252
uggacggaga acugauaagg gc 22

<210> 253
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 253
uuuugugacc gacacuaacg gg 22

<210> 254
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 254

ucagguaccu gaaguagcgc gc 1119-10CON-PCT.ST25 22

<210> 255
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 255
cauugcacuu gucccggccu au 22

<210> 256
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 256
ugauugucca aacgcaauuc uu 22

<210> 257
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 257
uaggaacuuc auaccgugcu cu 22

<210> 258
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 258
uaaaugcacu aucugguacg ac 22

<210> 259
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 259
ucggugggac uuucguccgu uu 22

<210> 260
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 260
uugguucccu ucaaccagcu gu 22

<210> 261
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 261
ugacuagauc cacacucauu aa 22

1119-10CON-PCT.ST25

<210> 262
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 262
aggugcauug uagucgcauu gu 22

<210> 263
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 263
uguauuuacg uugcauuga aa 22

<210> 264
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 264
ugucauggaa uugcucucuu ug 22

<210> 265
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 265
aaucuagccu cuacuaggcu uu 22

<210> 266
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 266
uaaaauaucag cugguaauuc ug 22

<210> 267
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 267
ugaagucagc aacuugauuc ca 22

<210> 268
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 268
uggcagugug guuagcuggu ug 22

1119-10CON-PCT.ST25

<210> 269
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 269
uaaggcacgc ggugaaugcc aa 22

<210> 270
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 270
uaaagcuaga uuaccaaagc au 22

<210> 271
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 271
uaggaacuua auaccgugcu cu 22

<210> 272
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 272
uugugcgugu gacagcggu au 22

<210> 273
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 273
jagcaccauu cgaaucagu gc 22

<210> 274
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 274
iaccguaaa uccgaacuug ug 22

<210> 275
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 275
iaugcacua gucccggccu gc 22

1119-10CON-PCT.ST25

<210> 276
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 276
ugacuagacc gaacacucgu gc 22

<210> 277
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 277
uguguugaaa aucguuugca cg 22

<210> 278
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 278
uugagcaaaa uuucaggugu gu 22

<210> 279
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 279
cuuggcacug ggagaauuca ca 22

<210> 280
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 280
uuucaugucg auuucuuuuc au 22

<210> 281
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 281
uaaaauuuua aguggagccu gc 22

<210> 282
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 282
ugagaucauu uugaaagcug au 22

<210> 283

1119-10CON-PCT.ST25

<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 283
uuuagguuuc acaggaaacu gg 22

<210> 284
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 284
uggcaagaug ucggaauagc ug 22

<210> 285
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 285
uaaucucaau uuguaaaugu ga 22

<210> 286
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 286
auuguacuuc aucaggugcu cu 22

<210> 287
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 287
ucuuugguau ucuagcugua ga 22

<210> 288
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 288
ucagguacuu agugacucuc aa 22

<210> 289
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 289
ucuuugguga uuuuagcugu au 22

<210> 290
<211> 22

1119-10CON-PCT.ST25

<212> RNA
<213> Drosophila melanogaster
<400> 290
ucccugagac ccuaacuugu ga 22

<210> 291
<211> 22
<212> RNA
<213> Drosophila melanogaster
<400> 291
ucacaaccuc cuugagugag cg 22

<210> 292
<211> 22
<212> RNA
<213> Drosophila melanogaster
<400> 292
aaucacagga uuauacugug ag 22

<210> 293
<211> 22
<212> RNA
<213> Drosophila melanogaster
<400> 293
uggcaagaug ucggcauagc ug 22

<210> 294
<211> 22
<212> RNA
<213> Drosophila melanogaster
<400> 294
gcacugggua aaguuugucc ua 22

<210> 295
<211> 22
<212> RNA
<213> Drosophila melanogaster
<400> 295
uauugcacac uucccggccu uu 22

<210> 296
<211> 22
<212> RNA
<213> Drosophila melanogaster
<400> 296
uauugcacau ucaccggccu ga 22

<210> 297
<211> 22
<212> RNA

1119-10CON-PCT.ST25

<213> Drosophila melanogaster

<400> 297

uauugcacuu gagacggccu ga

22

<210> 298

<211> 22

<212> RNA

<213> Drosophila melanogaster

<400> 298

uauugcacuu uucacagccc ga

22

<210> 299

<211> 21

<212> RNA

<213> Drosophila melanogaster

<400> 299

uauucgagcc aaauaguucg g

21

<210> 300

<211> 22

<212> RNA

<213> Drosophila melanogaster

<400> 300

uuuugauugu ugcucagaaa gc

22

<210> 301

<211> 22

<212> RNA

<213> Drosophila melanogaster

<400> 301

ugucuuuuuc cgcuuacugg cg

22

<210> 302

<211> 22

<212> RNA

<213> Drosophila melanogaster

<400> 302

ugaacacagc uggugguauca ca

22

<210> 303

<211> 22

<212> RNA

<213> Drosophila melanogaster

<400> 303

ucacugggcu uuguuuauca ca

22

<210> 304

<211> 22

<212> RNA

<213> Drosophila melanogaster

1119-10CON-PCT.ST25

<400> 304
uaucaacagcc agcuuugaug gg

22

<210> 305
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 305
acguauacug aauguauccu ga

22

<210> 306
<211> 22
<212> RNA
<213> Drosophila melanogaster

<400> 306
cgguauaccu ucaguauacg ua

22

<210> 307
<211> 22
<212> RNA
<213> Artificial

<220>
<223> Anti-microRNA molecule

<400> 307
cacaaguucg gaucuacggg uu

22

<210> 308
<211> 22
<212> RNA
<213> Artificial

<220>
<223> Anti-microRNA molecule

<400> 308
cauagcccug uacaugcug cu

22

<210> 309
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 309
ccacaggagu cugagcauuu ga

22

<210> 310
<211> 22
<212> RNA
<213> Artificial

1119-10CON-PCT.ST25

<220>
<223> anti-microRNA molecule

<400> 310
uaccugcacu guaagcacuu uu 22

<210> 311
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 311
uaucugcacu gucagcacuu ua 22

<210> 312
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 312
gauagcccug uacaaugcug cu 22

<210> 313
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 313
acaaauucgg uucuacaggg ua 22

<210> 314
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 314
gaaagagacc gguucacugu ga 22

<210> 315
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 315

1119-10CON-PCT.ST25

augcccuuuc aucauugcac ug

22

<210> 316
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 316
uccgugguuc uacccugugg ua

22

<210> 317
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 317
guagugcuuu cuacuuuauug gg

22

<210> 318
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 318
uacuagacug ugagcuccuc ga

22

<210> 319
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 319
ccccuauac gauuagcauu aa

22

<210> 320
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 320
cucaccgaca gcguugaauug uu

22

<210> 321

1119-10CON-PCT.ST25

<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 321
cccaccgaca gcaaugaaug uu

22

<210> 322
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 322
acucaccgac agguugaaug uu

22

<210> 323
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 323
ugugaguucu accauugcca aa

22

<210> 324
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 324
agugaauucu accagugcca ua

22

<210> 325
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 325
acccuauca guucuccguc ca

22

<210> 326
<211> 22
<212> RNA
<213> Artificial

1119-10CON-PCT.ST25

<220>
<223> anti-microRNA molecule

<400> 326
ucaggaacug ccuuucucuc ca

22

<210> 327
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 327
agcccaaaag gagaauucuu ug

22

<210> 328
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 328
ccggcugcaa cacaagacac ga

22

<210> 329
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 329
cugcaaacc ugcauguggg ag

22

<210> 330
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 330
accuccacc augcaaggga ug

22

<210> 331
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 331

1119-10CON-PCT.ST25

cugauaucag cucaguaggc ac

22

<210> 332
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 332
accuaauaua ucaaacauau ca

22

<210> 333
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 333
agcugcuuuu gggauuccgu ug

22

<210> 334
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 334
uggcugucaa uucauagguc ag

22

<210> 335
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 335
acugggacuu uguaggccag uu

22

<210> 336
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 336
ucaucuugcc cgcaaagacc ca

22

<210> 337

1119-10CON-PCT.ST25

<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 337
uccacaugga guugcuguua ca

22

<210> 338
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 338
ugccaauauu ucugugcugc ua

22

<210> 339
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 339
cccaacaaca ugaaacuacc ua

22

<210> 340
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 340
gcugggugga gaagguggug aa

22

<210> 341
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 341
gaaccuau cu cccucugga cc

22

<210> 342
<211> 22
<212> RNA
<213> Artificial

1119-10CON-PCT.ST25

<220>
<223> anti-microRNA molecule

<400> 342
uaaccaaugu gcagacuacu gu 22

<210> 343
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 343
aacagguagu cugaacacug gg 22

<210> 344
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 344
aacagauagu cuaaacacug gg 22

<210> 345
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 345
acaucguuac cagacagugu ua 22

<210> 346
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 346
ucauuaccag gcaguauuag ag 22

<210> 347
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 347

1119-10CON-PCT.ST25

uccaucauua cccggcagua uu

22

<210> 348
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 348
cuaguggucc uaaacauuuc ac

22

<210> 349
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 349
aggcauagga ugacaaaggg aa

22

<210> 350
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 350
cagacuccgg uggaugaag ga

22

<210> 351
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 351
ccacacacuu ccuacauuc ca

22

<210> 352
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 352
acaagcuuuu ugcucgucuu au

22

<210> 353

1119-10CON-PCT.ST25

<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 353
ucagccgcug uacacgcac ag

22

<210> 354
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 354
aggcgaagga ugacaaaggg aa

22

<210> 355
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 355
uggccgugac uggagacugu ua

22

<210> 356
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 356
gguacauca acggucgaug gu

22

<210> 357
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 357
acugccuguc ugugccugcu gu

22

<210> 358
<211> 22
<212> RNA
<213> Artificial

1119-10CON-PCT.ST25

<220>
<223> anti-microRNA molecule

<400> 358
ugucuguc aa uucauagguc au

22

<210> 359
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 359
ucacaguugc cagcugagau ua

22

<210> 360
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 360
ccaaucauu ccugaugcag ua

22

<210> 361
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 361
cacaugguua gaucaagcac aa

22

<210> 362
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 362
aagaauugcg uuuggacaau ca

22

<210> 363
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 363

1119-10CON-PCT.ST25

caaaguguca gauacggugu gg

22

<210> 364
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 364
aaacccagca gacaauguag cu

22

<210> 365
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 365
gaccaguag ccagauguag cu

22

<210> 366
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 366
ugggguauuu gacaaacuga ca

22

<210> 367
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 367
aaacggaacc acuagugacu ug

22

<210> 368
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 368
cucaauagac ugugagcucc uu

22

<210> 369

1119-10CON-PCT.ST25

<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 369
gaaagugccc ccacaguuug ag

22

<210> 370
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 370
aacaggauug agggggggcc cu

22

<210> 371
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 371
auguaugugg gacgguaaac ca

22

<210> 372
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 372
cuuugacaau acuauugcac ug

22

<210> 373
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 373
caccaaaaca uggaagcacu ua

22

<210> 374
<211> 22
<212> RNA
<213> Artificial

1119-10CON-PCT.ST25

<220>

<223> anti-microRNA molecule

<400> 374

cuuccaguca aggauguua ca

22

<210> 375

<211> 22

<212> RNA

<213> Artificial

<220>

<223> anti-microRNA molecule

<400> 375

ucgcccucuc aaccagcuu uu

22

<210> 376

<211> 22

<212> RNA

<213> Artificial

<220>

<223> anti-microRNA molecule

<400> 376

cgaaccaca auccuggcu ua

22

<210> 377

<211> 22

<212> RNA

<213> Artificial

<220>

<223> anti-microRNA molecule

<400> 377

gauacagcag caaucaugu uu

22

<210> 378

<211> 22

<212> RNA

<213> Artificial

<220>

<223> anti-microRNA molecule

<400> 378

agaggucgac cgugaaugu gc

22

<210> 379

<211> 22

<212> RNA

<213> Artificial

<220>

<223> anti-microRNA molecule

<400> 379

1119-10CON-PCT.ST25

ccagcagcac cuggggcagu gg

22

<210> 380
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 380
caccaaugcc cuaggggaug cg

22

<210> 381
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 381
ggcuggagga agggcccaga gg

22

<210> 382
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 382
acggaagggc agagagggcc ag

22

<210> 383
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 383
aaaaagguua gcugggugug uu

22

<210> 384
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 384
acaaccagcu aagacacugc ca

22

<210> 385

1119-10CON-PCT.ST25

<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 385
caaucagcua augacacugc cu

22

<210> 386
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 386
caaucagcua acuacacugc cu

22

<210> 387
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 387
acaggccggg acaagugcaa ua

22

<210> 388
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 388
cuaccugcac gaacagcacu uu

22

<210> 389
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 389
ugcucaauaa auacccguug aa

22

<210> 390
<211> 22
<212> RNA
<213> Artificial

1119-10CON-PCT.ST25

<220>
<223> anti-microRNA molecule

<400> 390
gcaaaaaugu gcuagugcca aa 22

<210> 391
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 391
aacaauacaa cuuacuaccu ca 22

<210> 392
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 392
uaccugcacu guuagcacuu ug 22

<210> 393
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 393
acacaaauuc gguucuacag gg 22

<210> 394
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 394
cacauaggaa ugaaaagcca ua 22

<210> 395
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 395

1119-10CON-PCT.ST25

acaaaguucu gugaugcacu ga

22

<210> 396
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 396
uccucaagga gccucagucu ag

22

<210> 397
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 397
ccccuauac aauuagcauu aa

22

<210> 398
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 398
aacagguagu cuaaacacug gg

22

<210> 399
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 399
ucaucauuac caggcaguau ua

22

<210> 400
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 400
ucuagugguc cuaaacauuu ca

22

<210> 401

1119-10CON-PCT.ST25

<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 401
aggcaaagga ugacaaaggg aa

22

<210> 402
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 402
ccagucaguu ccugaugcag ua

22

<210> 403
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 403
aaacggaacc acuagugacu ua

22

<210> 404
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 404
uccagcagcu cacaaucuag ug

22

<210> 405
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 405
aaaagugccc ccuaguuug ag

22

<210> 406
<211> 22
<212> RNA
<213> Artificial

1119-10CON-PCT.ST25

<220>

<223> anti-microRNA molecule

<400> 406

gcacacaaag uggaagcacu uu

22

<210> 407

<211> 22

<212> RNA

<213> Artificial

<220>

<223> anti-microRNA molecule

<400> 407

agagagggcc uccacuuuga ug

22

<210> 408

<211> 22

<212> RNA

<213> Artificial

<220>

<223> anti-microRNA molecule

<400> 408

cacucaaaac cuggcggcac uu

22

<210> 409

<211> 22

<212> RNA

<213> Artificial

<220>

<223> anti-microRNA molecule

<400> 409

caaaagagcc cccaguuuga gu

22

<210> 410

<211> 22

<212> RNA

<213> Artificial

<220>

<223> anti-microRNA molecule

<400> 410

acacuacaaa cucugcggca cu

22

<210> 411

<211> 22

<212> RNA

<213> Artificial

<220>

<223> anti-microRNA molecule

<400> 411

1119-10CON-PCT.ST25

acacacaaaa gggaagcacu uu

22

<210> 412
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 412
gacucaaaag uaguagcacu uu

22

<210> 413
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 413
acaugcacau gcacacauac au

22

<210> 414
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 414
ggaagaacag ccuuccucug cc

22

<210> 415
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 415
gaagagagcu ugcccuugca ua

22

<210> 416
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 416
cagcuaugcc agcaucuugc cu

22

<210> 417

1119-10CON-PCT.ST25

<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 417
gguguugcag cgcuucaugu uu 22

<210> 418
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 418
cacuuacuga gcaccuacua gg 22

<210> 419
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 419
gacuggagga agggcccaga gg 22

<210> 420
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 420
cucugcaggc ccugugcuuu gc 22

<210> 421
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 421
guucuaggau aggcccaggg gc 22

<210> 422
<211> 22
<212> RNA
<213> Artificial

1119-10CON-PCT.ST25

<220>
<223> anti-microRNA molecule

<400> 422
aaggcaucau auaggagcug aa

22

<210> 423
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 423
caacaaaauc acugaugcug ga

22

<210> 424
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 424
gugagcuccu ggaggacagg ga

22

<210> 425
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 425
gcuauaaagu aacugagacg ga

22

<210> 426
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 426
gacugaccga ccgaccgauc ga

22

<210> 427
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 427

cgggugcgau uucuguguga ga	1119-10CON-PCT.ST25	22
<210> 428		
<211> 22		
<212> RNA		
<213> Artificial		
<220>		
<223> anti-microRNA molecule		
<400> 428		
cagucaggcu uuggcuagau ca		22
<210> 429		
<211> 22		
<212> RNA		
<213> Artificial		
<220>		
<223> anti-microRNA molecule		
<400> 429		
agcacuggac uaggggucag ca		22
<210> 430		
<211> 22		
<212> RNA		
<213> Artificial		
<220>		
<223> anti-microRNA molecule		
<400> 430		
gaggcaggca cucgggcaga ca		22
<210> 431		
<211> 22		
<212> RNA		
<213> Artificial		
<220>		
<223> anti-microRNA molecule		
<400> 431		
aaucagcuaa uuacacugcc ua		22
<210> 432		
<211> 22		
<212> RNA		
<213> Artificial		
<220>		
<223> anti-microRNA molecule		
<400> 432		
gaaaguguau gggcuuugug aa		22
<210> 433		

1119-10CON-PCT.ST25

<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 433
ggcucaaagg gcuccucagg ga

22

<210> 434
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 434
caacaaauc acaagucuuc ca

22

<210> 435
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 435
ucaggccggg acaagugcaa ua

22

<210> 436
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 436
uaccugcacg aacagcacuu ug

22

<210> 437
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 437
acuacccuca ugccccucaa gg

22

<210> 438
<211> 22
<212> RNA
<213> Artificial

1119-10CON-PCT.ST25

<220>
<223> anti-microRNA molecule

<400> 438
ccaaaaguaa cuagcacacc ac

22

<210> 439
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 439
cauuuuucgu uauugcucuu ga

22

<210> 440
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 440
gagacuagau auggaagggg ga

22

<210> 441
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 441
auacugggca cacggaggga ga

22

<210> 442
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 442
agcugggcga cccagaggga ca

22

<210> 443
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 443

agagguuaag acagcagggc ug	1119-10CON-PCT.ST25	22
<210> 444		
<211> 22		
<212> RNA		
<213> Artificial		
<220>		
<223> anti-microRNA molecule		
<400> 444		
guacuaugca accuacuacu cu		22
<210> 445		
<211> 22		
<212> RNA		
<213> Artificial		
<220>		
<223> anti-microRNA molecule		
<400> 445		
guaccccugg agauucugau aa		22
<210> 446		
<211> 22		
<212> RNA		
<213> Artificial		
<220>		
<223> anti-microRNA molecule		
<400> 446		
ucacaccuag guuccaagga uu		22
<210> 447		
<211> 22		
<212> RNA		
<213> Artificial		
<220>		
<223> anti-microRNA molecule		
<400> 447		
uuacagaugg auaccgugca au		22
<210> 448		
<211> 22		
<212> RNA		
<213> Artificial		
<220>		
<223> anti-microRNA molecule		
<400> 448		
ggaccaaucg ccgucccccgc cg		22
<210> 449		

1119-10CON-PCT.ST25

<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 449
auaaggauuu uuaggggcau ua

22

<210> 450
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 450
gguucaguug uucaaccagu ua

22

<210> 451
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 451
aacuauacaa ccuacuaccu ca

22

<210> 452
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 452
cucacacuug aggucucagg ga

22

<210> 453
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 453
cuacauacuu cuuuacauuc ca

22

<210> 454
<211> 22
<212> RNA
<213> Artificial

1119-10CON-PCT.ST25

<220>
<223> anti-microRNA molecule

<400> 454
cacaucaaag cuggcuguga ua

22

<210> 455
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 455
caaccagcua accacacugc cu

22

<210> 456
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 456
acugcuaguu uccacccggu ga

22

<210> 457
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 457
caugcgaauu uucacccggu ga

22

<210> 458
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 458
acugcaagug uucacccggu ga

22

<210> 459
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 459

acuccaguuu uucucccggu ga 1119-10CON-PCT.ST25 22

<210> 460
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 460
caagcugauu uacacccggu ga 22

<210> 461
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 461
uuagcugaug uacacccggu ga 22

<210> 462
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 462
uaggugauuu uucacccggu ga 22

<210> 463
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 463
cucuguagau guuaacccgg ug 22

<210> 464
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 464
cgacagcaag uaaacuguga ua 22

<210> 465

1119-10CON-PCT.ST25

<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 465
aagcugaaug ugucucuagu ca

22

<210> 466
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 466
aagcugaaug ugucucuagu ca

22

<210> 467
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 467
ugaagagagc gacuccauga ca

22

<210> 468
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 468
ugaagagagc gccuccauga ca

22

<210> 469
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 469
cgcaucuacu gagccuaccu ca

22

<210> 470
<211> 22
<212> RNA
<213> Artificial

1119-10CON-PCT.ST25

<220>
<223> anti-microRNA molecule

<400> 470
ucugcagcuu cucguggugc uu

22

<210> 471
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 471
cccaagaaua ccagacauau ca

22

<210> 472
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 472
acauggauag gagcuacggg ua

22

<210> 473
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 473
cacggaaaca uauguacggg ug

22

<210> 474
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 474
cacggaaaca aauguacggg ug

22

<210> 475
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 475

1119-10CON-PCT.ST25

cggauuauga agauuacggg ua

22

<210> 476
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 476
ucagcagaaa cuuauacggg ua

22

<210> 477
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 477
cucagcggaa acauuacggg ua

22

<210> 478
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 478
acacagcucg aucuacaggg ua

22

<210> 479
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 479
auugccguac ugaacgaucu ca

22

<210> 480
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 480
aucauccuga uaaacgauuc ga

22

<210> 481

1119-10CON-PCT.ST25

<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 481
gaacuagaaa augugcauaa ua

22

<210> 482
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 482
agaugaguaa cgguucuagu ca

22

<210> 483
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 483
cuguaagcua gauuacauau ca

22

<210> 484
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 484
uuccaacucg cuucaguguc au

22

<210> 485
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 485
ucgguaacgc uucaguguca ua

22

<210> 486
<211> 22
<212> RNA
<213> Artificial

1119-10CON-PCT.ST25

<220>

<223> anti-microRNA molecule

<400> 486

ucgguuacgc uucaguguca ua

22

<210> 487

<211> 22

<212> RNA

<213> Artificial

<220>

<223> anti-microRNA molecule

<400> 487

cacaucccua aucaguguca ug

22

<210> 488

<211> 22

<212> RNA

<213> Artificial

<220>

<223> anti-microRNA molecule

<400> 488

uacucuuucu aggagguugu ga

22

<210> 489

<211> 22

<212> RNA

<213> Artificial

<220>

<223> anti-microRNA molecule

<400> 489

gucuacacuu uugagucuuc ga

22

<210> 490

<211> 22

<212> RNA

<213> Artificial

<220>

<223> anti-microRNA molecule

<400> 490

uucuacacuu uuuaauuuuc ga

22

<210> 491

<211> 22

<212> RNA

<213> Artificial

<220>

<223> anti-microRNA molecule

<400> 491

1119-10CON-PCT.ST25

uggaaacacc aacgacguau ua

22

<210> 492
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 492
cguucacuaac ccaugucuuu ca

22

<210> 493
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 493
cagcuaugcc aacaucuugc cu

22

<210> 494
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 494
cugaacugcc uacaucuugc ca

22

<210> 495
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 495
uguagacugc cauuucuugc ca

22

<210> 496
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 496
ugaagccggu ugguaagcuuu aa

22

<210> 497

1119-10CON-PCT.ST25

<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 497
ucaaggcuuc aucaacaacg aa

22

<210> 498
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 498
uggacagcua uggccugaug aa

22

<210> 499
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 499
agcacaaca accaggccuc ca

22

<210> 500
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 500
agcuuuggua accuagcuuu au

22

<210> 501
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 501
guucagaauc augucgaaag cu

22

<210> 502
<211> 22
<212> RNA
<213> Artificial

1119-10CON-PCT.ST25

<220>

<223> anti-microRNA molecule

<400> 502

cggcuuucuaa cuaaugaucu ca

22

<210> 503

<211> 22

<212> RNA

<213> Artificial

<220>

<223> anti-microRNA molecule

<400> 503

acuagcuuuc acgaugaucu ca

22

<210> 504

<211> 22

<212> RNA

<213> Artificial

<220>

<223> anti-microRNA molecule

<400> 504

acuggcuuuc acgaugaucu ca

22

<210> 505

<211> 22

<212> RNA

<213> Artificial

<220>

<223> anti-microRNA molecule

<400> 505

uuacugaauu uauauggugc ua

22

<210> 506

<211> 22

<212> RNA

<213> Artificial

<220>

<223> anti-microRNA molecule

<400> 506

uacaauauua cauacuaccu ca

22

<210> 507

<211> 22

<212> RNA

<213> Artificial

<220>

<223> anti-microRNA molecule

<400> 507

1119-10CON-PCT.ST25

acgacuuuuc aaauacuuug ua

22

<210> 508
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 508
acuguggcaa agcauucacu ua

22

<210> 509
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 509
gcacaccuga aacuuugcuc ac

22

<210> 510
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 510
ggggcatauca aacaacauau ca

22

<210> 511
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 511
guggcatauca ccgcgugccu ua

22

<210> 512
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 512
ugugaauuca ugcagugcca uu

22

<210> 513

1119-10CON-PCT.ST25

<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 513
ggaaaagaua accaguguca uu

22

<210> 514
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 514
cuccugucg cacaacuaau ac

22

<210> 515
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 515
cugccuguug aucacgagcu ua

22

<210> 516
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 516
cacgcaguu aaugcauu ua

22

<210> 517
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 517
cccgcacaug cgcauugcuc aa

22

<210> 518
<211> 22
<212> RNA
<213> Artificial

1119-10CON-PCT.ST25

<220>
<223> anti-microRNA molecule

<400> 518
aaagguauu cucgagcaau aa

22

<210> 519
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 519
ucaggccggg gagagugcaa ua

22

<210> 520
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 520
gcgucauuac cugacaguau ua

22

<210> 521
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 521
gcuguucgag aaucucagg ga

22

<210> 522
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 522
cugaauaggca ucggaguaca aa

22

<210> 523
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 523

1119-10CON-PCT.ST25

caguaccuau guguaguaca aa

22

<210> 524
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 524
caguacuuuu guguaguaca aa

22

<210> 525
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 525
agcgaagauu ugggggccag ua

22

<210> 526
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 526
gucauuucuc gcaccuaccu ca

22

<210> 527
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 527
cucgaagcaa aggccuacgc aa

22

<210> 528
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 528
auaucccgcc gcgaucguac cg

22

<210> 529

1119-10CON-PCT.ST25

<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 529
uaccacuuug uacaaccaa ga

22

<210> 530
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 530
gagcuacuug gaggggacca au

22

<210> 531
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 531
agcuccuacc cgaaacaugu aa

22

<210> 532
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 532
agaagagaau aggcucuagu ca

22

<210> 533
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 533
gagcguauc cgugcacgug ua

22

<210> 534
<211> 22
<212> RNA
<213> Artificial

1119-10CON-PCT.ST25

<220>
<223> anti-microRNA molecule

<400> 534
gcaacgcuca aaaguccugu ga 22

<210> 535
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 535
ccaugccaac aguugacugu ga 22

<210> 536
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 536
uaagagcggc accacuacuu aa 22

<210> 537
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 537
uuaccugcgg cacuacuacu ua 22

<210> 538
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 538
uggucagugu uagugaggug ug 22

<210> 539
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 539

1119-10CON-PCT.ST25

cuacagucgc gaaagauuug ca

22

<210> 540
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 540
guacagucuu cuaugcauuc ca

22

<210> 541
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 541
ucacugggua cuccugauac uc

22

<210> 542
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 542
uaaaaggauu ccucucaaaa cc

22

<210> 543
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 543
ccagauuagg augagauuua cu

22

<210> 544
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 544
uccuacaaga guucgacauc ac

22

<210> 545

1119-10CON-PCT.ST25

<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 545
caccgugaaa acuaaaaagc ua

22

<210> 546
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 546
guaucagaaa acaucgagaa ac

22

<210> 547
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 547
cccauaacaa caaccacccg cc

22

<210> 548
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 548
aaauaccacc cuuccucccu ca

22

<210> 549
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 549
aagcuuugcc aaagucuugc cu

22

<210> 550
<211> 22
<212> RNA
<213> Artificial

1119-10CON-PCT.ST25

<220>
<223> anti-microRNA molecule

<400> 550
auugcagcag acacuucacg gg 22

<210> 551
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 551
caaacugcuu cuaauucuug cc 22

<210> 552
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 552
caaguuuugc cagagucuug cc 22

<210> 553
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 553
aucuccacug cuacaucaug cc 22

<210> 554
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 554
cgaaugcuuu cccacccggc ga 22

<210> 555
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 555

1119-10CON-PCT.ST25

cuuccaaaca cccaugccua ca

22

<210> 556
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 556
agcagccgac acaguacggg ca

22

<210> 557
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 557
gaauucuucc agugccauua ac

22

<210> 558
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 558
gcccuaauca guucuccguc ca

22

<210> 559
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 559
cccguuagug ucggucacaa aa

22

<210> 560
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 560
gcgcgcuacu ucagguaccu ga

22

<210> 561

1119-10CON-PCT.ST25

<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 561
auaggccggg acaagugcaa ug

22

<210> 562
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 562
aagaauugcg uuuggacaau ca

22

<210> 563
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 563
agagcacggu augaaguucc ua

22

<210> 564
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 564
gucguaccag auagugcauu ua

22

<210> 565
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 565
aaacggacga aagucccacc ga

22

<210> 566
<211> 22
<212> RNA
<213> Artificial

1119-10CON-PCT.ST25

<220>
<223> anti-microRNA molecule

<400> 566
acagcugguu gaaggggacc aa 22

<210> 567
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 567
uuaaugagug uggaucuagu ca 22

<210> 568
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 568
acaaugcgac uacaugcac cu 22

<210> 569
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 569
uuucauauugc aacguaaaau ca 22

<210> 570
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 570
caaagagagc aaauccauga ca 22

<210> 571
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 571

1119-10CON-PCT.ST25

aaagccuagu agaggcuaga uu

22

<210> 572
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 572
cagaauuacc agcugauuu ua

22

<210> 573
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 573
uggaaucaag uugcugacuu ca

22

<210> 574
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 574
caaccagcua accacacugc ca

22

<210> 575
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 575
uuggcauuc cgcgugccu ua

22

<210> 576
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 576
augcuuuggu aaucagcuu ua

22

<210> 577

1119-10CON-PCT.ST25

<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 577
agagcacggu auuaaguucc ua

22

<210> 578
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 578
auagccgcug ucacacgcac aa

22

<210> 579
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 579
gcacugauuu cgaauggugc ua

22

<210> 580
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 580
cacaaguucg gauuuacggg uu

22

<210> 581
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 581
gcaggccggg acuagugcaa uu

22

<210> 582
<211> 22
<212> RNA
<213> Artificial

1119-10CON-PCT.ST25

<220>
<223> anti-microRNA molecule

<400> 582
gcacgagugu ucggucuagu ca 22

<210> 583
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 583
cgugcaaacg auuuucaaca ca 22

<210> 584
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 584
acacaccuga aauuuugcuc aa 22

<210> 585
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 585
ugugaauucu cccagugcca ag 22

<210> 586
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 586
augaaaugaa aucgacauga aa 22

<210> 587
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 587

1119-10CON-PCT.ST25

gcaggcucca cuuaauauu ua

22

<210> 588
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 588
aucagcuuuc aaaaugaucu ca

22

<210> 589
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 589
ccaguuuccu gugaaaccua aa

22

<210> 590
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 590
cagcuauucc gacauuugc ca

22

<210> 591
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 591
ucacauuuac aaauugagau ua

22

<210> 592
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 592
agagcaccug augaaguaca au

22

<210> 593

1119-10CON-PCT.ST25

<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 593
ucuacagcua gaauaccaaa ga

22

<210> 594
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 594
uugagaguca cuaaguaccu ga

22

<210> 595
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 595
auacagcuaa aaucaccaaa ga

22

<210> 596
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 596
ucacaaguua gggucucagg ga

22

<210> 597
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 597
cgcucacuca aggagguugu ga

22

<210> 598
<211> 22
<212> RNA
<213> Artificial

1119-10CON-PCT.ST25

<220>

<223> anti-microRNA molecule

<400> 598

cucacaguau aauccuguga uu

22

<210> 599

<211> 22

<212> RNA

<213> Artificial

<220>

<223> anti-microRNA molecule

<400> 599

cagcuaugcc gacauuugc ca

22

<210> 600

<211> 22

<212> RNA

<213> Artificial

<220>

<223> anti-microRNA molecule

<400> 600

uaggacaaac uuuacccagu gc

22

<210> 601

<211> 22

<212> RNA

<213> Artificial

<220>

<223> anti-microRNA molecule

<400> 601

aaaggccggg aagugugcaa ua

22

<210> 602

<211> 22

<212> RNA

<213> Artificial

<220>

<223> anti-microRNA molecule

<400> 602

ucaggccggu gaaugugcaa ua

22

<210> 603

<211> 22

<212> RNA

<213> Artificial

<220>

<223> anti-microRNA molecule

<400> 603

ucaggccguc ucaagugcaa ua	1119-10CON-PCT.ST25	22
<210> 604		
<211> 22		
<212> RNA		
<213> Artificial		
<220>		
<223> anti-microRNA molecule		
<400> 604		
ucgggcugug aaaagugcaa ua		22
<210> 605		
<211> 21		
<212> RNA		
<213> Artificial		
<220>		
<223> anti-microRNA molecule		
<400> 605		
ccgaacuuau uggcucgaau a		21
<210> 606		
<211> 22		
<212> RNA		
<213> Artificial		
<220>		
<223> anti-microRNA molecule		
<400> 606		
gcuuucugag caacaaucaa aa		22
<210> 607		
<211> 22		
<212> RNA		
<213> Artificial		
<220>		
<223> anti-microRNA molecule		
<400> 607		
cgccaguaag cggaaaaaga ca		22
<210> 608		
<211> 22		
<212> RNA		
<213> Artificial		
<220>		
<223> anti-microRNA molecule		
<400> 608		
uggauaccac cagcuguguu ca		22
<210> 609		

1119-10CON-PCT.ST25

<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 609
ugagauaaac aaagcccagu ga

22

<210> 610
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 610
cccaucaaag cuggcuguga ua

22

<210> 611
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 611
ucaggauaca uucaguauac gu

22

<210> 612
<211> 22
<212> RNA
<213> Artificial

<220>
<223> anti-microRNA molecule

<400> 612
uacguauacu gaagguauac cg

22

<210> 613
<211> 23
<212> RNA
<213> Artificial

<220>
<223> 2'-O-methyl microRNA molecule

<220>
<221> misc_structure
<222> (23)..(23)
<223> 3' aminolinker attached to the a nucleotide at position 23

<400> 613
gucaacauca gucugauaag cua

23

1119-10CON-PCT.ST25

<210> 614
<211> 21
<212> RNA
<213> Artificial

<220>
<223> 2'-O-methyl antisense molecule

<220>
<221> misc_structure
<222> (21)..(21)
<223> 3' aminolinker attached to the u nucleotide at position 21

<400> 614
aaggcaagcu gaccugaag u 21

<210> 615
<211> 21
<212> RNA
<213> Artificial

<220>
<223> 2' O- methyl reverse sequence

<220>
<221> misc_structure
<222> (21)..(21)
<223> 3' aminolinker attached to the a nucleotide at position 21

<400> 615
ugaaguccca gucgaacgga a 21

<210> 616
<211> 26
<212> DNA
<213> Artificial

<220>
<223> 2'-deoxy microRNA molecule

<220>
<221> misc_structure
<222> (26)..(26)
<223> 3' aminolinker attached to the g nucleotide at position 26

<400> 616
gtcaacatca gtctgataag ctagcg 26

<210> 617
<211> 24
<212> DNA
<213> Artificial

<220>
<223> 2'-deoxy antisense molecule

<220>

1119-10CON-PCT.ST25

<221> misc_structure
<222> (24)..(24)
<223> 3' aminolinker attached to the g nucleotide at position 24

<400> 617
aaggcaagct gaccctgaag tgcg 24

<210> 618
<211> 88
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 618
gaacaattgc ttttacagat gcacatatcg aggtgaacat cacgtacgtc aacatcagtc 60
tgataagcta tcggttggca gaagctat 88

<210> 619
<211> 90
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 619
ggcataaaga attgaagaga gttttcactg catacgacga ttctgtgatt tgtattcagc 60
ccatatcggtt tcatagcttc tgccaaccga 90

<210> 620
<211> 35
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 620
taatacgact cactatagaa caattgcttt tacag 35

<210> 621
<211> 35
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 621
atttaggtga cactataggc ataaagaatt gaaga 35

<210> 622
<211> 33
<212> DNA

1119-10CON-PCT.ST25

<213> Artificial

<220>

<223> synthetic oligonucleotide molecule

<400> 622

ggcctcaaca tcagtctgat aagctaggta cct

33

<210> 623

<211> 33

<212> DNA

<213> Artificial

<220>

<223> synthetic oligonucleotide molecule

<400> 623

ggccaggtac ctagcttatac agactgatgt tga

33